The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research Report: Human TOP2B (UniProt Q02880) — Functional Annotation and Current Evidence

0. Target verification (gene/protein identity)

The research target is human TOP2B (UniProt Q02880), DNA topoisomerase II beta (EC 5.6.2.2), a type II DNA topoisomerase. The retrieved literature explicitly describes human TOP2B as a nuclear enzyme that uses ATP-dependent strand passage via transient, enzyme-linked double-strand breaks (DSBs), matching the UniProt description and the type II topoisomerase family/domain expectations (ling2022acomprehensivestructural pages 1-4, ling2022acomprehensivestructural pages 4-5).

1. Key concepts, definitions, and current understanding

1.1 What TOP2B is (core definition)

DNA topoisomerase IIβ (TOP2B) is a type II topoisomerase that changes DNA topology by an ATP-dependent strand-passage reaction. Mechanistically, one duplex DNA segment (“G-DNA”, gate) is transiently cleaved to create an enzyme-bridged break, and a second duplex (“T-DNA”, transported) is passed through; the G-DNA is then religated, and ATP hydrolysis resets the enzyme cycle (ling2022acomprehensivestructural pages 1-4, ling2022acomprehensivestructural pages 4-5).

1.2 Catalytic reaction and substrate specificity

Substrate: duplex DNA; co-substrate/energy source: ATP. TOP2B couples DNA cleavage/religation and DNA transport to ATP binding/hydrolysis (ling2022acomprehensivestructural pages 1-4, ling2022acomprehensivestructural pages 4-5, ling2022acomprehensivestructural pages 14-15).

Key biochemical/structural points relevant for functional annotation:
- TOP2B “modulates DNA topology using energy from ATP hydrolysis” (ling2022acomprehensivestructural pages 1-4).
- Strand passage requires ATP hydrolysis, though cleavage can occur without ATP (ling2022acomprehensivestructural pages 1-4).
- The N-terminal ATPase domain has a Bergerat/GHKL fold; E103 acts as a catalytic base for ATP hydrolysis (E103A abolishes ATP hydrolysis) (ling2022acomprehensivestructural pages 4-5, ling2022acomprehensivestructural pages 14-15).
- Reported ATPase kinetic parameters (construct-dependent): e.g., Km ~0.115 mM for ATP for a 45–444 ATPase-domain construct (ling2022acomprehensivestructural pages 12-14).

1.3 Functional meaning of “TOP2B cleavage complexes”

During catalysis, TOP2B forms covalent, enzyme-linked DNA cleavage intermediates (“TOP2Bcc”). These can be trapped by topoisomerase poisons (e.g., etoposide) and are biologically important because processing of trapped cleavage complexes can yield DNA damage signals and DSBs (segev2024mappingcatalyticallyengaged pages 1-3, segev2024mappingcatalyticallyengaged pages 3-5).

2. Biological roles and pathways (mechanism-first functional annotation)

2.1 Primary cellular role: resolving transcription-associated torsional stress and shaping transcriptional programs

Current evidence supports TOP2B as a major regulator of transcription-associated topology. In neurons, TOP2B helps resolve torsional stress generated by transcription and is linked to regulated gene-expression programs, including immediate early/stress response transcription (segev2024mappingcatalyticallyengaged pages 1-3, segev2024mappingcatalyticallyengaged pages 3-5).

A 2024 Cell Reports study provides genome-scale evidence by mapping catalytically engaged TOP2B in neurons via etoposide-trapped covalent complexes (TOP2Bcc-seq) (segev2024mappingcatalyticallyengaged pages 3-5):
- Experimental trapping condition: etoposide 50 μM for 30 min (segev2024mappingcatalyticallyengaged pages 3-5).
- Genome-wide called peaks: n = 35,505 (segev2024mappingcatalyticallyengaged pages 3-5).
- Agreement with occupancy mapping: TOP2Bcc-seq correlated with prior TOP2B ChIP-seq (Spearman 0.64) but shows distinct distribution emphasizing catalytic engagement rather than mere binding (segev2024mappingcatalyticallyengaged pages 3-5).
- Distribution: TOP2B catalytic engagement is relatively depleted at promoters/TSSs and enriched across gene bodies and active chromatin/transcription states (segev2024mappingcatalyticallyengaged pages 3-5).

These results support a model where TOP2B’s catalytic function is frequently deployed within transcribed regions to manage topological constraints rather than being limited to promoter-localized binding (segev2024mappingcatalyticallyengaged pages 3-5).

2.2 TOP2B-mediated DSBs as regulated transcriptional features in neurons

In post-mitotic neurons, multiple lines of evidence connect TOP2B activity to regulated DSB formation used for transcriptional responses (segev2024mappingcatalyticallyengaged pages 1-3, roberts2024adaptiveandmaladaptive pages 4-5). A 2024 review synthesizing the field notes that neuronal stimulation can increase TOP2B association/activation at immediate early genes, with a reported five-fold increase in IEG-bound TOP2B upon NMDA stimulation in cited work; the same review also describes calcineurin-dependent regulation (Ca2+ influx → calcineurin → TOP2B dephosphorylation) of activity-induced breaks (roberts2024adaptiveandmaladaptive pages 4-5).

In the 2024 neuronal TOP2Bcc mapping study, processing of etoposide-stabilized TOP2Bcc produced DNA break signaling (γH2AX near sites), supporting that TOP2B catalytic engagement can be associated with DNA damage responses when cleavage complexes are stabilized/processed (segev2024mappingcatalyticallyengaged pages 3-5).

2.3 Chromatin/genome-organization connections

TOP2B catalytic engagement and/or binding has been reported to occur in open chromatin and at architectural protein sites (CTCF/cohesin) in neurons, suggesting possible roles at the interface of transcription and genome organization (segev2024mappingcatalyticallyengaged pages 1-3, segev2024mappingcatalyticallyengaged pages 21-22). The 2024 mapping study reports TOP2B activity correlates with chromosomal compartment organization and nucleosome configuration (segev2024mappingcatalyticallyengaged pages 3-5).

3. Subcellular localization

TOP2B is primarily a nuclear enzyme. Structural work on human TOP2B states that the C-terminal domain contains nuclear localization signals and many phosphorylation sites, consistent with nuclear chromatin-associated function (ling2022acomprehensivestructural pages 1-4).

4. Recent developments and latest research (prioritizing 2023–2024)

4.1 2024: High-resolution mapping of catalytically engaged TOP2B in neurons

A key 2024 advance is the ability to distinguish occupancy from catalytic engagement by mapping trapped TOP2B cleavage complexes genome-wide (TOP2Bcc-seq). Quantitative metrics (etoposide condition, peak counts, correlation with ChIP-seq) and distributional conclusions (depletion at TSS/promoters, enrichment in gene bodies/active transcription states) provide actionable functional-annotation evidence (segev2024mappingcatalyticallyengaged pages 3-5).

A representative visual schematic and workflow figure from the Segev et al. 2024 paper was retrieved (segev2024mappingcatalyticallyengaged media a5cd6a98, segev2024mappingcatalyticallyengaged media f7fb478a, segev2024mappingcatalyticallyengaged media 0a9d03ba, segev2024mappingcatalyticallyengaged media b23724f1).

4.2 2024: Adaptive vs maladaptive DNA breaks in Alzheimer’s disease (AD) and TOP2B expression changes

A 2024 study of human frontal cortex nuclei (AD vs non-demented controls) used CUT&RUN targeting poly(ADP-ribose) (PAR) to map DNA break-associated signal, reporting a striking global increase in PAR peaks but loss at nervous-system genes:
- Sample size: AD n = 3, ND n = 3 male donors (age 78–91) (zhang2024lossofadaptive pages 1-2).
- Global change: AD brains contained 19.9× more PAR peaks than non-demented brains (zhang2024lossofadaptive pages 1-2).
- Yet adaptive breaks at nervous-system genes were “profoundly lost” and gene expression downregulated, consistent with the model that activity-dependent breaks support transcription of neuronal genes (zhang2024lossofadaptive pages 1-2).

This work also reports reduced TOP2B in AD brains at the protein/cell-count level:
- TOP2B-positive cells by IHC quantification (3 ND vs 3 AD): 82.4 ± 7.0 (ND) vs 21.7 ± 9.3 (AD), p < 0.05 (zhang2024lossofadaptive pages 9-13).
- The authors interpret this as consistent with reduced TOP2B-linked adaptive DSB physiology in AD, while acknowledging causal direction is not yet established (zhang2024lossofadaptive pages 9-13).

A complementary 2024 review frames these findings as part of a broader concept: neuronal activity–induced “adaptive” breaks versus pathological “maladaptive” break accumulation, and notes limitations of proxy markers (γH2AX, PAR) compared to direct break mapping (roberts2024adaptiveandmaladaptive pages 7-8).

5. Current applications and real-world implementations

5.1 Cardio-oncology: anthracycline cardiotoxicity implicates TOP2B

A major real-world relevance of TOP2B is its connection to anthracycline cardiotoxicity (doxorubicin class). A 2024 review summarizes the evolution of mechanisms and provides dose-risk statistics for late cardiotoxicity/heart failure, while highlighting Top2β involvement and the role of dexrazoxane in revealing it:
- Cumulative doxorubicin thresholds and risks: ~5% cardiomyopathy/CHF at 400 mg/m², and elevated incidence at higher cumulative doses; the review also cites >35% incidence of dilated cardiomyopathy at 650 mg/m² and notes thresholds ~550 mg/m² (or 450 mg/m² with additional risks) (szponar2024evolutionoftheories pages 1-2).

5.2 Human iPSC-cardiomyocyte assays for TOP2-inhibitor cardiotoxicity profiling (2024)

A 2024 PLOS Genetics study provides a quantitative, human-cell-based framework to profile TOP2 inhibitor (TOP2i) responses in cardiomyocytes (iPSC-CMs) and references TOP2B’s mechanistic importance:
- Six iPSC-CM donor lines (healthy females, ages 21–32); median purity 97% (range 63–100%) (matthews2024anthracyclinesinducecardiotoxicity pages 3-5).
- Dose–response viability assays: 0.01–50 μM for 48 h (matthews2024anthracyclinesinducecardiotoxicity pages 3-5).
- Median LD50 (μM): DOX 14.02, DNR 0.98, EPI 3.79, MTX 0.98 (matthews2024anthracyclinesinducecardiotoxicity pages 3-5).
- Clinically motivated transcriptomic dose: 0.5 μM for deeper characterization (matthews2024anthracyclinesinducecardiotoxicity pages 3-5).
- Differentially expressed genes (DEGs):
- 3 h: DOX 19; EPI 210; DNR 532; MTX 75; TRZ 0 (matthews2024anthracyclinesinducecardiotoxicity pages 5-7)
- 24 h: DOX 6,645; EPI 6,328; DNR 7,017; MTX 1,115; TRZ 0 (matthews2024anthracyclinesinducecardiotoxicity pages 5-7)
- The paper notes that TOP2B is essential for cardiotoxicity in mouse models and that disruption of TOP2B in iPSC-CMs can reduce doxorubicin sensitivity (reported as background/interpretive context) (matthews2024anthracyclinesinducecardiotoxicity pages 2-3).

These data illustrate how TOP2B-centered mechanisms are being operationalized into translational assay systems for drug safety and cardiotoxicity-risk biology (matthews2024anthracyclinesinducecardiotoxicity pages 5-7, matthews2024anthracyclinesinducecardiotoxicity pages 2-3, matthews2024anthracyclinesinducecardiotoxicity pages 3-5).

6. Expert opinions and analysis (authoritative synthesis)

6.1 Mechanistic consensus: TOP2B links transcriptional topology management to regulated DNA break physiology

Recent authoritative synthesis emphasizes that TOP2B is not merely a “DNA damage enzyme” but rather a topology enzyme whose normal catalytic cycle uses transient cleavage intermediates; in specialized contexts (notably neurons), these breaks can be co-opted into regulated transcription programs (segev2024mappingcatalyticallyengaged pages 1-3, roberts2024adaptiveandmaladaptive pages 4-5).

6.2 Disease-context interpretation: “adaptive breaks lost despite net break gain” in AD

An expert-level interpretive point emerging from 2024 evidence is that AD brains may show more global DNA-break signal while simultaneously losing the specific, regulated break landscape at nervous-system genes that supports neuronal gene expression. The 19.9× global PAR peak increase alongside “profound” loss at nervous-system genes illustrates this dissociation (zhang2024lossofadaptive pages 1-2). The reported reduction in TOP2B-positive cells provides a plausible mechanistic link but is not yet proven causal (zhang2024lossofadaptive pages 9-13).

7. Statistics and recent data (selected highlights)

Key quantitative findings from recent studies are summarized below and in the evidence table artifact.

• Neuronal TOP2Bcc mapping (2024): etoposide 50 μM/30 min; 35,505 peaks; correlation with TOP2B ChIP-seq Spearman 0.64 (segev2024mappingcatalyticallyengaged pages 3-5).
• AD brain adaptive break mapping (2024): 19.9× more PAR peaks in AD globally; TOP2B-positive cells 82.4 ± 7.0 (ND) vs 21.7 ± 9.3 (AD); PAR+ cells 74.4 ± 10.5% (AD) vs 16.8 ± 6.9% (ND) (zhang2024lossofadaptive pages 1-2, zhang2024lossofadaptive pages 9-13, zhang2024lossofadaptive pages 2-5).
• iPSC-CM TOP2 inhibitor cardiotoxicity profiling (2024): median LD50s (μM) DOX 14.02; DNR 0.98; EPI 3.79; MTX 0.98; DEGs at 24 h up to ~7,017 (DNR) under 0.5 μM exposure (matthews2024anthracyclinesinducecardiotoxicity pages 3-5, matthews2024anthracyclinesinducecardiotoxicity pages 5-7).
• Clinical cardio-oncology dose–risk statistics summarized in recent reviews: e.g., CHF/cardiomyopathy rates 5% at 400 mg/m², 26% at 550 mg/m², 48% at 700 mg/m² in cited clinical contexts (matthews2024anthracyclinesinducecardiotoxicity pages 2-3).

Evidence summary table

Table: This table condenses the main mechanistic and 2024 quantitative findings relevant to human TOP2B, spanning enzymology, neuronal genomic mapping, Alzheimer’s disease brain DNA-break physiology, and cardiotoxicity-related iPSC-cardiomyocyte data. It is useful as a rapid evidence summary for functional annotation and disease-context interpretation.

Primary sources (URLs and publication dates)

• Segev A, Heady L, Crewe M, Madabhushi R. Mapping catalytically engaged TOP2B in neurons reveals the principles of topoisomerase action within the genome. Cell Reports. Feb 2024. https://doi.org/10.1016/j.celrep.2024.113809 (segev2024mappingcatalyticallyengaged pages 3-5, segev2024mappingcatalyticallyengaged media a5cd6a98)
• Zhang X, Haeri M, Swerdlow RH, Wang N. Loss of Adaptive DNA Breaks in Alzheimer’s Disease Brains. Journal of Alzheimer’s Disease. Jan 2024. https://doi.org/10.3233/jad-231303 (zhang2024lossofadaptive pages 1-2, zhang2024lossofadaptive pages 9-13)
• Roberts A, Swerdlow RH, Wang N. Adaptive and Maladaptive DNA Breaks in Neuronal Physiology and Alzheimer’s Disease. International Journal of Molecular Sciences. Jul 2024. https://doi.org/10.3390/ijms25147774 (roberts2024adaptiveandmaladaptive pages 4-5, roberts2024adaptiveandmaladaptive pages 7-8)
• Matthews ER, Johnson OD, Horn KJ, et al. Anthracyclines induce cardiotoxicity through a shared gene expression response signature. PLOS Genetics. Feb 2024. https://doi.org/10.1371/journal.pgen.1011164 (matthews2024anthracyclinesinducecardiotoxicity pages 3-5, matthews2024anthracyclinesinducecardiotoxicity pages 5-7, matthews2024anthracyclinesinducecardiotoxicity pages 2-3)
• Szponar J, Ciechanski E, Ciechanska M, et al. Evolution of Theories on Doxorubicin-Induced Late Cardiotoxicity-Role of Topoisomerase. International Journal of Molecular Sciences. Dec 2024. https://doi.org/10.3390/ijms252413567 (szponar2024evolutionoftheories pages 1-2)
• Ling EM, Baslé A, Cowell IG, et al. A comprehensive structural analysis of the ATPase domain of human DNA topoisomerase II beta… Structure. Aug 2022. https://doi.org/10.1016/j.str.2022.05.009 (ling2022acomprehensivestructural pages 1-4, ling2022acomprehensivestructural pages 12-14)

Notes and limitations

• While the report prioritizes 2024 sources for biological roles and disease connections, detailed structural enzymology in the retrieved set came from a high-quality 2022 structural paper; newer structural studies may exist but were not retrieved in the current tool run (ling2022acomprehensivestructural pages 1-4).
• Some neuron-centric mechanistic claims in reviews rely on earlier primary literature (not fully retrieved here) and are therefore cited as review synthesis rather than direct re-analysis.

References

1. (ling2022acomprehensivestructural pages 1-4): Elise M. Ling, Arnaud Baslé, Ian G. Cowell, Bert van den Berg, Tim R. Blower, and Caroline A. Austin. A comprehensive structural analysis of the atpase domain of human dna topoisomerase ii beta bound to amppnp, adp, and the bisdioxopiperazine, icrf193. Structure, 30:1129-1145.e3, Aug 2022. URL: https://doi.org/10.1016/j.str.2022.05.009, doi:10.1016/j.str.2022.05.009. This article has 24 citations and is from a domain leading peer-reviewed journal.

2. (ling2022acomprehensivestructural pages 4-5): Elise M. Ling, Arnaud Baslé, Ian G. Cowell, Bert van den Berg, Tim R. Blower, and Caroline A. Austin. A comprehensive structural analysis of the atpase domain of human dna topoisomerase ii beta bound to amppnp, adp, and the bisdioxopiperazine, icrf193. Structure, 30:1129-1145.e3, Aug 2022. URL: https://doi.org/10.1016/j.str.2022.05.009, doi:10.1016/j.str.2022.05.009. This article has 24 citations and is from a domain leading peer-reviewed journal.

3. (ling2022acomprehensivestructural pages 14-15): Elise M. Ling, Arnaud Baslé, Ian G. Cowell, Bert van den Berg, Tim R. Blower, and Caroline A. Austin. A comprehensive structural analysis of the atpase domain of human dna topoisomerase ii beta bound to amppnp, adp, and the bisdioxopiperazine, icrf193. Structure, 30:1129-1145.e3, Aug 2022. URL: https://doi.org/10.1016/j.str.2022.05.009, doi:10.1016/j.str.2022.05.009. This article has 24 citations and is from a domain leading peer-reviewed journal.

4. (ling2022acomprehensivestructural pages 12-14): Elise M. Ling, Arnaud Baslé, Ian G. Cowell, Bert van den Berg, Tim R. Blower, and Caroline A. Austin. A comprehensive structural analysis of the atpase domain of human dna topoisomerase ii beta bound to amppnp, adp, and the bisdioxopiperazine, icrf193. Structure, 30:1129-1145.e3, Aug 2022. URL: https://doi.org/10.1016/j.str.2022.05.009, doi:10.1016/j.str.2022.05.009. This article has 24 citations and is from a domain leading peer-reviewed journal.

5. (segev2024mappingcatalyticallyengaged pages 1-3): Amir Segev, Lance Heady, Morgan Crewe, and Ram Madabhushi. Mapping catalytically engaged top2b in neurons reveals the principles of topoisomerase action within the genome. Cell reports, 43:113809-113809, Feb 2024. URL: https://doi.org/10.1016/j.celrep.2024.113809, doi:10.1016/j.celrep.2024.113809. This article has 10 citations and is from a highest quality peer-reviewed journal.

6. (segev2024mappingcatalyticallyengaged pages 3-5): Amir Segev, Lance Heady, Morgan Crewe, and Ram Madabhushi. Mapping catalytically engaged top2b in neurons reveals the principles of topoisomerase action within the genome. Cell reports, 43:113809-113809, Feb 2024. URL: https://doi.org/10.1016/j.celrep.2024.113809, doi:10.1016/j.celrep.2024.113809. This article has 10 citations and is from a highest quality peer-reviewed journal.

7. (roberts2024adaptiveandmaladaptive pages 4-5): Anysja Roberts, Russell H. Swerdlow, and Ning Wang. Adaptive and maladaptive dna breaks in neuronal physiology and alzheimer’s disease. International Journal of Molecular Sciences, 25:7774, Jul 2024. URL: https://doi.org/10.3390/ijms25147774, doi:10.3390/ijms25147774. This article has 4 citations.

8. (segev2024mappingcatalyticallyengaged pages 21-22): Amir Segev, Lance Heady, Morgan Crewe, and Ram Madabhushi. Mapping catalytically engaged top2b in neurons reveals the principles of topoisomerase action within the genome. Cell reports, 43:113809-113809, Feb 2024. URL: https://doi.org/10.1016/j.celrep.2024.113809, doi:10.1016/j.celrep.2024.113809. This article has 10 citations and is from a highest quality peer-reviewed journal.

9. (segev2024mappingcatalyticallyengaged media a5cd6a98): Amir Segev, Lance Heady, Morgan Crewe, and Ram Madabhushi. Mapping catalytically engaged top2b in neurons reveals the principles of topoisomerase action within the genome. Cell reports, 43:113809-113809, Feb 2024. URL: https://doi.org/10.1016/j.celrep.2024.113809, doi:10.1016/j.celrep.2024.113809. This article has 10 citations and is from a highest quality peer-reviewed journal.

10. (segev2024mappingcatalyticallyengaged media f7fb478a): Amir Segev, Lance Heady, Morgan Crewe, and Ram Madabhushi. Mapping catalytically engaged top2b in neurons reveals the principles of topoisomerase action within the genome. Cell reports, 43:113809-113809, Feb 2024. URL: https://doi.org/10.1016/j.celrep.2024.113809, doi:10.1016/j.celrep.2024.113809. This article has 10 citations and is from a highest quality peer-reviewed journal.

11. (segev2024mappingcatalyticallyengaged media 0a9d03ba): Amir Segev, Lance Heady, Morgan Crewe, and Ram Madabhushi. Mapping catalytically engaged top2b in neurons reveals the principles of topoisomerase action within the genome. Cell reports, 43:113809-113809, Feb 2024. URL: https://doi.org/10.1016/j.celrep.2024.113809, doi:10.1016/j.celrep.2024.113809. This article has 10 citations and is from a highest quality peer-reviewed journal.

12. (segev2024mappingcatalyticallyengaged media b23724f1): Amir Segev, Lance Heady, Morgan Crewe, and Ram Madabhushi. Mapping catalytically engaged top2b in neurons reveals the principles of topoisomerase action within the genome. Cell reports, 43:113809-113809, Feb 2024. URL: https://doi.org/10.1016/j.celrep.2024.113809, doi:10.1016/j.celrep.2024.113809. This article has 10 citations and is from a highest quality peer-reviewed journal.

13. (zhang2024lossofadaptive pages 1-2): Xiaoyu Zhang, Mohammad Haeri, Russell H. Swerdlow, and Ning Wang. Loss of adaptive dna breaks in alzheimer’s disease brains. Journal of Alzheimer's Disease, 97:1861-1875, Jan 2024. URL: https://doi.org/10.3233/jad-231303, doi:10.3233/jad-231303. This article has 7 citations and is from a peer-reviewed journal.

14. (zhang2024lossofadaptive pages 9-13): Xiaoyu Zhang, Mohammad Haeri, Russell H. Swerdlow, and Ning Wang. Loss of adaptive dna breaks in alzheimer’s disease brains. Journal of Alzheimer's Disease, 97:1861-1875, Jan 2024. URL: https://doi.org/10.3233/jad-231303, doi:10.3233/jad-231303. This article has 7 citations and is from a peer-reviewed journal.

15. (roberts2024adaptiveandmaladaptive pages 7-8): Anysja Roberts, Russell H. Swerdlow, and Ning Wang. Adaptive and maladaptive dna breaks in neuronal physiology and alzheimer’s disease. International Journal of Molecular Sciences, 25:7774, Jul 2024. URL: https://doi.org/10.3390/ijms25147774, doi:10.3390/ijms25147774. This article has 4 citations.

16. (szponar2024evolutionoftheories pages 1-2): Jaroslaw Szponar, Erwin Ciechanski, Magda Ciechanska, Jaroslaw Dudka, and Sławomir Mandziuk. Evolution of theories on doxorubicin-induced late cardiotoxicity-role of topoisomerase. International Journal of Molecular Sciences, 25:13567, Dec 2024. URL: https://doi.org/10.3390/ijms252413567, doi:10.3390/ijms252413567. This article has 23 citations.

17. (matthews2024anthracyclinesinducecardiotoxicity pages 3-5): E. Renee Matthews, Omar D. Johnson, Kandace J. Horn, José A. Gutiérrez, Simon R. Powell, and Michelle C. Ward. Anthracyclines induce cardiotoxicity through a shared gene expression response signature. PLOS Genetics, 20:e1011164, Feb 2024. URL: https://doi.org/10.1371/journal.pgen.1011164, doi:10.1371/journal.pgen.1011164. This article has 14 citations and is from a domain leading peer-reviewed journal.

18. (matthews2024anthracyclinesinducecardiotoxicity pages 5-7): E. Renee Matthews, Omar D. Johnson, Kandace J. Horn, José A. Gutiérrez, Simon R. Powell, and Michelle C. Ward. Anthracyclines induce cardiotoxicity through a shared gene expression response signature. PLOS Genetics, 20:e1011164, Feb 2024. URL: https://doi.org/10.1371/journal.pgen.1011164, doi:10.1371/journal.pgen.1011164. This article has 14 citations and is from a domain leading peer-reviewed journal.

19. (matthews2024anthracyclinesinducecardiotoxicity pages 2-3): E. Renee Matthews, Omar D. Johnson, Kandace J. Horn, José A. Gutiérrez, Simon R. Powell, and Michelle C. Ward. Anthracyclines induce cardiotoxicity through a shared gene expression response signature. PLOS Genetics, 20:e1011164, Feb 2024. URL: https://doi.org/10.1371/journal.pgen.1011164, doi:10.1371/journal.pgen.1011164. This article has 14 citations and is from a domain leading peer-reviewed journal.

20. (zhang2024lossofadaptive pages 2-5): Xiaoyu Zhang, Mohammad Haeri, Russell H. Swerdlow, and Ning Wang. Loss of adaptive dna breaks in alzheimer’s disease brains. Journal of Alzheimer's Disease, 97:1861-1875, Jan 2024. URL: https://doi.org/10.3233/jad-231303, doi:10.3233/jad-231303. This article has 7 citations and is from a peer-reviewed journal.

21. (matthews2024anthracyclinesinducecardiotoxicity pages 20-21): E. Renee Matthews, Omar D. Johnson, Kandace J. Horn, José A. Gutiérrez, Simon R. Powell, and Michelle C. Ward. Anthracyclines induce cardiotoxicity through a shared gene expression response signature. PLOS Genetics, 20:e1011164, Feb 2024. URL: https://doi.org/10.1371/journal.pgen.1011164, doi:10.1371/journal.pgen.1011164. This article has 14 citations and is from a domain leading peer-reviewed journal.

22. (matthews2024anthracyclinesinducecardiotoxicity pages 21-23): E. Renee Matthews, Omar D. Johnson, Kandace J. Horn, José A. Gutiérrez, Simon R. Powell, and Michelle C. Ward. Anthracyclines induce cardiotoxicity through a shared gene expression response signature. PLOS Genetics, 20:e1011164, Feb 2024. URL: https://doi.org/10.1371/journal.pgen.1011164, doi:10.1371/journal.pgen.1011164. This article has 14 citations and is from a domain leading peer-reviewed journal.

Artifacts

• Edison artifact artifact-00
  

Citations

1. ling2022acomprehensivestructural pages 1-4
2. ling2022acomprehensivestructural pages 12-14
3. segev2024mappingcatalyticallyengaged pages 3-5
4. roberts2024adaptiveandmaladaptive pages 4-5
5. zhang2024lossofadaptive pages 1-2
6. zhang2024lossofadaptive pages 9-13
7. roberts2024adaptiveandmaladaptive pages 7-8
8. szponar2024evolutionoftheories pages 1-2
9. matthews2024anthracyclinesinducecardiotoxicity pages 3-5
10. matthews2024anthracyclinesinducecardiotoxicity pages 5-7
11. matthews2024anthracyclinesinducecardiotoxicity pages 2-3
12. ling2022acomprehensivestructural pages 4-5
13. ling2022acomprehensivestructural pages 14-15
14. segev2024mappingcatalyticallyengaged pages 1-3
15. segev2024mappingcatalyticallyengaged pages 21-22
16. zhang2024lossofadaptive pages 2-5
17. matthews2024anthracyclinesinducecardiotoxicity pages 20-21
18. matthews2024anthracyclinesinducecardiotoxicity pages 21-23
19. https://doi.org/10.1016/j.celrep.2024.113809
20. https://doi.org/10.3233/jad-231303
21. https://doi.org/10.3390/ijms25147774
22. https://doi.org/10.1371/journal.pgen.1011164
23. https://doi.org/10.3390/ijms252413567
24. https://doi.org/10.1016/j.str.2022.05.009
25. https://doi.org/10.1016/j.str.2022.05.009,
26. https://doi.org/10.1016/j.celrep.2024.113809,
27. https://doi.org/10.3390/ijms25147774,
28. https://doi.org/10.3233/jad-231303,
29. https://doi.org/10.3390/ijms252413567,
30. https://doi.org/10.1371/journal.pgen.1011164,

TOP2B (DNA Topoisomerase II Beta) – Function, Roles, and Current Insights

Overview and Key Concepts

TOP2B (DNA topoisomerase IIβ) is a human enzyme that controls DNA topology by cutting and rejoining DNA strands. It is one of two isoforms of DNA topoisomerase II in humans (the other being TOP2A) (pmc.ncbi.nlm.nih.gov). Topoisomerase II enzymes transiently cleave both strands of a DNA double helix, pass another segment of double-stranded DNA through this break, then reseal the break (www.genecards.org). This ATP-dependent “cut-and-pass-through” mechanism relaxes DNA supercoils and resolves DNA entanglements (catenanes) (pmc.ncbi.nlm.nih.gov) (www.genecards.org). TOP2B plays a “decatenating” role, enabling chromosome strands to separate and relieving torsional stress in DNA (www.genecards.org). Human TOP2B is a large, ~1,626-amino-acid protein (~180 kDa) encoded on chromosome 3 (TOP2A is on chromosome 17), and it belongs to the type II topoisomerase family characterized by an N-terminal ATPase domain and a central DNA-cleavage core domain (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The C-terminal region of TOP2B is poorly conserved relative to TOP2A – it is intrinsically disordered and mediates unique protein-protein interactions (pmc.ncbi.nlm.nih.gov).

Catalytic Activity: TOP2B’s enzymatic activity is classified under EC 5.6.2.2, reflecting ATP-dependent double-stranded DNA breakage and rejoining (www.genecards.org). In practical terms, TOP2B can relax both positive and negative DNA supercoils and untangle interlinked DNA loops (pmc.ncbi.nlm.nih.gov) (www.genecards.org). During its catalytic cycle, TOP2B binds two DNA duplexes: it introduces a transient double-strand break in one DNA (the “G-segment”) and passes the second duplex (the “T-segment”) through the break before ligating the DNA back together (www.genecards.org). This reaction consumes ATP and results in a change of DNA linking number by ±2, effectively removing supercoils or catenanes that form during DNA replication and transcription (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Notably, TOP2B forms a covalent enzyme-DNA intermediate (a TOP2B–DNA cleavage complex) during strand cleavage (pmc.ncbi.nlm.nih.gov). Under normal conditions these cleavage complexes are transient, but if they stall or abort they can become permanent DNA double-strand breaks (DSBs) (pmc.ncbi.nlm.nih.gov). Such abortive TOP2B breaks are dangerous lesions that threaten genome stability (pmc.ncbi.nlm.nih.gov).

TOP2B vs. TOP2A: The β isoform (TOP2B) arose from a gene duplication and shares core mechanistic functions with TOP2A, but the two are non-redundant in vivo (pmc.ncbi.nlm.nih.gov). TOP2A is essential for proliferating cells – it is highly expressed in S/G2-phases and is crucial for chromosome condensation and segregation during mitosis (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). By contrast, TOP2B is expressed ubiquitously (including in non-dividing cells like neurons) (www.genecards.org) and is dispensable for initial cell proliferation but critical for specialized DNA transactions such as gene transcription and developmental processes (pmc.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). The two isoforms have highly similar ATPase and DNA-cleavage domains, but differ in their C-terminal tails which confer different regulatory interactions (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). For example, TOP2A contains signals for mitotic chromatin targeting and is tightly regulated during the cell cycle, whereas TOP2B’s unique C-terminus allows engagement with transcriptional machinery and chromatin organizing factors (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In yeast, either isoform can fulfill the essential topoisomerase II function, but in mammals each has distinct roles that the other cannot fully substitute (pmc.ncbi.nlm.nih.gov). This distinction is evident in knockout models: Top2a deletion is lethal early in embryogenesis (due to failure of cell division), whereas Top2b knockout mice survive to late gestation but suffer specific developmental defects (notably in neural tissues) and die perinatally (pubmed.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). These observations underscore that TOP2B’s primary importance lies in post-replicative DNA processes, especially in gene regulation and differentiation.

Cellular Localization and Expression

TOP2B is predominantly a nuclear enzyme, functioning in the nucleus where it associates with chromatin. It is broadly expressed across tissues (reflecting its fundamental role in DNA metabolism) (www.genecards.org). In dividing cells both TOP2 isoforms are present, but in quiescent or terminally differentiated cells TOP2B becomes the dominant form as TOP2A levels decline (pmc.ncbi.nlm.nih.gov). For instance, during neuronal differentiation, TOP2A expression drops while TOP2B remains highly expressed, indicating a switch to reliance on TOP2B in mature neurons (pmc.ncbi.nlm.nih.gov). Immunolocalization and live-cell imaging studies show TOP2B is distributed throughout the nucleoplasm where transcription occurs (pmc.ncbi.nlm.nih.gov). A fraction may also localize to nucleoli under certain conditions (e.g. energy depletion or rRNA transcription stress) (academic.oup.com), but its primary site of action is the euchromatic regions of the nucleus. Notably, TOP2B tends to occupy open chromatin regions and is often found at genomic sites bound by architectural proteins such as CTCF and cohesin (pmc.ncbi.nlm.nih.gov). A 2021 machine-learning analysis of TOP2B ChIP-seq data showed that DNA accessibility and CTCF/cohesin binding were the strongest predictors of TOP2B binding across the genome (pmc.ncbi.nlm.nih.gov). In fact, just three features (DNase I hypersensitivity, CTCF, and cohesin) could explain a large portion of TOP2B’s binding profile (pmc.ncbi.nlm.nih.gov). This enrichment at CTCF/cohesin sites suggests TOP2B is strategically positioned at chromatin loop anchors and other regulatory elements to relieve supercoiling and torsional stress that accumulate during transcription or chromatin loop extrusion (pmc.ncbi.nlm.nih.gov). Thus, within the nucleus TOP2B dynamically scans and resolves topological problems, especially in active genes and at 3D chromosome domain boundaries.

Mechanistic Role in DNA Replication and Topology

Although TOP2A is the workhorse for DNA replication, TOP2B can also contribute to maintaining replication fork stability and resolving entanglements that arise during DNA synthesis. Recent evidence suggests TOP2B helps safeguard replication forks in certain contexts – for example, a 2024 study highlighted that TOP2B can recognize and cleave tangled DNA at stalled or stressed replication forks, helping to maintain fork integrity and progression (www.sciencedirect.com). Generally, during late S/G2 phase, type II topoisomerases remove inter-sister catenanes that form when replication forks converge. TOP2B has decatenation activity (pmc.ncbi.nlm.nih.gov)and can in principle fulfill this role, but in rapidly dividing cells TOP2A largely handles replication decatenation. Importantly, cells possess a “decatenation checkpoint” to ensure catenanes are resolved before mitosis; TOP2A’s C-terminal domain is known to regulate this checkpoint (pubmed.ncbi.nlm.nih.gov). TOP2B’s role in routine cell cycle decatenation is limited, but it may substitute if TOP2A is absent or inhibited – for instance, zebrafish embryos lacking Top2a can complete development only if maternal Top2b is present, underscoring some functional overlap (pmc.ncbi.nlm.nih.gov). In summary, TOP2B is capable of resolving DNA entanglements and supporting DNA replication topology, but under normal conditions it plays a secondary role to TOP2A in proliferating cells. Its essential contribution lies in managing DNA topology outside of replication, particularly in transcription-coupled scenarios.

TOP2B in Transcription and Chromatin Organization

One of the most critical functions of TOP2B is in facilitating gene transcription and regulating chromatin architecture. As RNA polymerase II (Pol II) transcribes DNA, it generates positive supercoils ahead of it and negative supercoils behind (pmc.ncbi.nlm.nih.gov). If unchecked, this supercoiling can stall transcription. Topoisomerases relieve this tension: TOP1 mainly nicks single strands, whereas TOP2 (including TOP2B) can remove heavier supercoils and knots by its double-strand passage mechanism (www.nature.com). TOP2B has emerged as a key player in releasing paused RNA polymerase II and enabling productive elongation (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Recent studies show that for certain inducible genes, Pol II pauses near the promoter after initiation (a checkpoint regulated by factors NELF/DSIF). The release of this pause and transition to elongation correlates with TOP2B creating a transient double-strand break near the promoter, which triggers local chromatin remodeling and recruitment of DNA damage response (DDR) factors (pmc.ncbi.nlm.nih.gov). This process involves the ATM kinase: a well-known 2015 study by H. Bunch et al. demonstrated that transcriptional elongation of some stimulus-responsive genes requires TOP2B-mediated DSBs and subsequent ATM signaling (pmc.ncbi.nlm.nih.gov). Specifically, induction of immediate-early genes (e.g. in neurons upon stimulation, or hormone-responsive genes) was blocked when TOP2B or ATM activity was inhibited (pmc.ncbi.nlm.nih.gov). In other words, TOP2B’s enzymatic cut not only relieves superhelical stress but also serves as a molecular signal – the resulting break is rapidly recognized by DDR proteins, and this signaling appears to facilitate release of Pol II into productive elongation (pmc.ncbi.nlm.nih.gov). This concept was summarized by Calderwood (2016) as a “novel role for topoisomerase IIβ in transcription,” where multiple gene activation events (heat shock, immediate-early, and nuclear receptor target genes) each require TOP2B-generated DSBs (pmc.ncbi.nlm.nih.gov). These TOP2B-induced breaks are normally repaired promptly (so the transcription-linked DNA damage is transient), but they underscore how intimately TOP2B is involved in transcription regulation via a controlled damage-and-repair mechanism**.

Beyond elongation, TOP2B contributes to higher-order genome organization. Chromatin is organized into loops and topologically associating domains (TADs) which bring enhancers and promoters together. The loop extrusion model suggests that cohesin complexes spool DNA into loops until they’re stopped by convergent CTCF sites (loop anchors). Ongoing transcription within loops generates torsional stress at the loop boundaries, and evidence indicates TOP2B localizes to these loop anchor regions (co-bound with CTCF/cohesin) to relieve accumulated supercoils (pmc.ncbi.nlm.nih.gov). By cutting and rejoining DNA at loop bases, TOP2B may help “reset” DNA topology, thereby maintaining stable contacts between regulatory elements and preventing persistent stress. In doing so, TOP2B indirectly influences gene expression by preserving 3D genome architecture (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). However, if TOP2B fails to religate or if its cleavage complexes persist at loop anchors, the outcome can be deleterious: collisions of transcription and replication or unresolved supercoils might convert TOP2B nicks into chromosome breakage (pmc.ncbi.nlm.nih.gov). Indeed, chromosomal translocations found in cancers often coincide with fragile sites where transcription-induced supercoiling and TOP2B activity are high (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). For example, one recent study (Lensing et al., 2016) showed TOP2B binding sites in the genome are associated with recurrent DNA breakpoints and mutations in cancer, highlighting TOP2B as both a “safeguard of genome integrity” and a contributor to mutagenic processes when misregulated (www.nature.com) (pmc.ncbi.nlm.nih.gov). In summary, TOP2B is crucial for maintaining transcriptional flow and genome organization, acting at the nexus of DNA topology and gene regulation. Its activity ensures genes can be turned on/off efficiently by preventing topological bottlenecks, but the same activity must be tightly controlled to avoid DNA damage.

Developmental and Cell-Type Specific Roles

Neuronal Development and Gene Expression

The importance of TOP2B in development was first apparent from mouse knockout studies. Top2b-null mice die at birth with severe neural defects, notably failure of proper axon guidance and elongation (pmc.ncbi.nlm.nih.gov). These mice cannot suckle and exhibit paralysis, indicating that TOP2B is indispensable for nervous system function (despite not being required for earlier embryonic cell divisions) (pmc.ncbi.nlm.nih.gov). Transcriptomic analyses of Top2b⁻/⁻ embryos revealed that relatively few genes change globally; however, a disproportionately large subset of developmentally regulated neuronal genes (≈30%) were mis-regulated in the absence of TOP2B (pubmed.ncbi.nlm.nih.gov). Many genes normally activated during later stages of neuronal differentiation failed to be properly induced (or repressed) without TOP2B, even though general housekeeping genes and early differentiation markers remained largely normal (pubmed.ncbi.nlm.nih.gov). This suggests TOP2B specifically enables the expression of genes required in late neuronal maturation (pubmed.ncbi.nlm.nih.gov). For example, one study found TOP2B is required for the timely expression of a brain potassium channel gene (Kcnd2) during neuronal differentiation (pubmed.ncbi.nlm.nih.gov). Mechanistically, TOP2B likely facilitates the large-scale transcriptional programs in neurons by resolving supercoils in long gene bodies and promoting chromatin changes at key gene promoters. Consistent with this, TOP2B protein is highly expressed in post-mitotic neurons and colocalizes with markers of active chromatin (pubmed.ncbi.nlm.nih.gov). It also interacts with chromatin regulators like HDAC2 in neurons (pubmed.ncbi.nlm.nih.gov), potentially linking TOP2B’s activity to chromatin remodeling. A 2023 analysis by King et al. found that Top2b-knockout neurons have dysregulation of genes controlling neurite outgrowth and survival, leading to premature neuronal death (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). One such gene affected is the neurotrophin receptor Ngfr (p75^NTR), whose aberrant upregulation in Top2b⁻/⁻ neurons contributes to apoptosis (pubmed.ncbi.nlm.nih.gov). These findings illustrate that TOP2B is tightly integrated into the gene networks that drive neuronal maturation and connectivity. By enabling the proper transcriptional activation of late-differentiation genes and repressing others, TOP2B helps choreograph complex developmental programs in the brain (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). The perinatal lethality of Top2b deficiency underscores that its role in the nervous system is indispensable.

B-Cell Development and Immunity

Another striking cell-type specific role for TOP2B has come to light in the immune system. In 2019, rare heterozygous mutations in human TOP2B were found to cause an immunodeficiency characterized by an absence of B cells (pmc.ncbi.nlm.nih.gov). Affected patients from multiple families had near-complete loss of circulating CD19⁺ B cells (with counts essentially 0, compared to hundreds per µL in healthy individuals) and severe hypogammaglobulinemia (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Notably, T cell numbers and function were normal, pointing to a B lineage–specific requirement for TOP2B (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This disorder, now termed “TOP2B deficiency syndrome,” revealed that human B-cell development is uniquely dependent on TOP2B’s DNA topology-modulating activity (pmc.ncbi.nlm.nih.gov). Follow-up studies in mice (using B cell–specific Top2b knockouts) confirmed a developmental block: bone marrow B progenitors failed to progress normally through early stages (Pre-Pro B to immature B), and peripheral B cells were greatly reduced (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The few B cells that did form were functionally impaired – they proliferated poorly in response to stimuli and produced little antibody upon antigen challenge (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). These phenotypes mirror the human immunodeficiency. At the molecular level, TOP2B loss in B progenitors led to reduced expression of key differentiation genes. For example, the transcription factor Pax5 (master regulator of B-cell commitment) was significantly downregulated in Top2b-deficient B cells, even though early lymphocyte genes like Rag1 remained unchanged (pmc.ncbi.nlm.nih.gov). This suggests TOP2B is necessary to properly activate certain large or topologically challenging gene loci during B-cell maturation – likely including the immunoglobulin heavy chain locus and factors like Pax5. The immunoglobulin heavy chain (IgH) gene is one of the largest in the genome and undergoes rapid transcription in developing B cells; TOP2B may relieve the extreme supercoiling generated during IgH transcription or V(D)J recombination. Additionally, TOP2B could be important for long-range chromatin loops at the IgH locus that bring distant gene segments together. Patients with TOP2B mutations show B cells “stuck” in development, highlighting that DNA topology must be correctly managed for B-cell differentiation to proceed (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). As one review noted, this finding “highlights the fundamental and unique dependency of B-cell progenitor differentiation on TOP2B-mediated DNA topological changes.” (pmc.ncbi.nlm.nih.gov). In summary, TOP2B is as critical to the immune system’s development as it is to the nervous system’s, reinforcing that its enzymatic action is not just globally important but also acutely required at specific genomic junctures in different cell lineages.

It is worth mentioning that other emerging links between TOP2B and human disease are being explored. For instance, certain hereditary hearing loss cases have been associated with dominant TOP2B mutations, posited to affect hair cell survival via altered PI3K–Akt signaling (pmc.ncbi.nlm.nih.gov). This suggests TOP2B’s role in gene regulation might extend to inner ear cells as well. Moreover, chronic neurodegenerative conditions like ataxia-telangiectasia (caused by ATM deficiency) show neuron loss that may be partly due to un-repaired TOP2B-induced breaks (pubmed.ncbi.nlm.nih.gov). These examples, while still under research, further illustrate how TOP2B’s activity intersects with critical cellular pathways and, when disturbed, can lead to tissue-specific pathologies.

Therapeutic and Real-World Implications

TOP2B’s pivotal role in managing DNA topology has made it a target (and unintended victim) of several drugs. Topoisomerase II enzymes are famously targeted by anti-cancer chemotherapeutics: drugs like doxorubicin (an anthracycline) and etoposide stabilize the Topo II cleavage complex on DNA, preventing re-ligation and thus causing lethal DNA breaks in rapidly dividing cancer cells (www.nature.com). These “Topo II poisons” do not discriminate between TOP2A and TOP2B, and their efficacy comes from inducing DNA damage, especially in proliferating cells where TOP2A is abundant (www.nature.com). However, TOP2B in non-dividing cells can also be trapped by these drugs, leading to side effects. A prime example is anthracycline cardiotoxicity: Doxorubicin, a widely used chemotherapy, can cause cumulative heart damage. Research in 2011–2012 uncovered that doxorubicin’s cardiac toxicity is largely mediated by TOP2B in cardiomyocytes (heart muscle cells, which are largely non-dividing). Doxorubicin-TOP2B complexes induce DNA breaks in cardiomyocytes, activating cell death pathways in the heart. Mice lacking Top2b in the heart are protected from doxorubicin injury, confirming TOP2B as the culprit for this side effect (pmc.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). This discovery directly led to changes in clinical practice: Dexrazoxane, a drug that inhibits TOP2B catalytic activity, is now used to protect the heart during anthracycline therapy (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). Dexrazoxane (approved as a cardioprotective agent) works by intercalating into Topo II’s ATPase sites and promoting degradation of TOP2B in cardiac cells (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). As a result, doxorubicin causes far fewer DNA breaks in the heart. Studies show dexrazoxane dramatically lowers TOP2B levels in cardiomyocytes within hours, and heart cells suffer less damage when TOP2B is at its lowest (pubmed.ncbi.nlm.nih.gov). This is a compelling real-world illustration of TOP2B biology: inhibiting Topo IIβ in a specific tissue (heart) can prevent lethal DNA damage without undermining the anti-cancer efficacy of a drug mostly directed at dividing cells (Topo IIα in tumors) (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov).

Another medical context involving TOP2B is secondary malignancies. Chemotherapy agents like etoposide and doxorubicin, while effective against primary tumors, are known to increase the risk of therapy-related leukemias. These leukemias often feature specific chromosomal translocations (for example, involving the MLL gene on 11q23) that bear signatures of Topo II-mediated DNA breaks. TOP2B in hematopoietic stem or progenitor cells can be trapped by these drugs, causing chromosomal breaks that misrepair into translocations (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Thus, TOP2B is implicated in the origin of some secondary cancers after chemotherapy. Modern research aims to mitigate these risks by developing isoform-specific Topo II inhibitors. For instance, scientists are searching for compounds that selectively inhibit TOP2A (to kill cancer cells) or TOP2B (to protect certain tissues). A recent development reported in 2025 is a molecule dubbed “Topobexin”, which targets the ATPase domain of Topo II and shows selective inhibition of TOP2B over TOP2A (pubmed.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In preclinical models, Topobexin was able to protect cardiac cells from anthracycline toxicity (similar to dexrazoxane) while sparing Topo IIα activity in cancer cells (pmc.ncbi.nlm.nih.gov). This strategy of isoform-selective modulation could improve chemotherapy outcomes by reducing side effects. Though Topobexin is not yet in clinical use (and as of 2025 was in research stages (pmc.ncbi.nlm.nih.gov)), it exemplifies how detailed knowledge of TOP2B structure and function is driving drug design.

Beyond cancer, there is growing interest in TOP2B as a therapeutic target in age-related diseases. Post-mitotic cells (like neurons and cardiomyocytes) accumulate DNA damage over time, and one hypothesis is that ongoing TOP2B activity contributes to this by inflicting low-level DNA breaks during transcription. A 2024 review in BBA Molecular Basis of Disease even suggested “targeting TOP2B as a vulnerability in aging”, noting that reducing Topo IIβ activity might diminish transcription-associated DNA damage and genomic instability in aging tissues (www.sciencedirect.com). In model organisms like C. elegans, partial knockdown of topoisomerase II was reported to extend lifespan, hinting that a lower TOP2B activity could be beneficial in certain contexts (pmc.ncbi.nlm.nih.gov). These findings are still preliminary, but they raise an intriguing point: while TOP2B is essential for normal physiology, excessive or unrestrained TOP2B activity might contribute to genomic wear-and-tear over a lifetime. It’s a delicate balance – too little TOP2B causes developmental failure (as seen in B cells and neurons), yet too much or persistent TOP2B action could underlie some degenerative changes. Future therapies might seek to fine-tune TOP2B activity: enhancing it where DNA topology problems cause disease, or dampening it where its activity exacerbates damage.

Expert Commentary and Current Research Directions

TOP2B sits at an intersection of DNA mechanics and gene regulation, and experts highlight its dual nature. On one hand, it is a “safeguard of genome integrity” (www.nature.com) – by resolving DNA tangles and supercoils, it prevents catastrophic chromosomal failures. On the other hand, its mechanism (cutting DNA) inherently risks genomic lesions if not properly controlled (pmc.ncbi.nlm.nih.gov). Jerry Nitiss, a leading topoisomerase researcher, noted that topoisomerases are “delicate enzymes” because “their catalytic intermediates [cleavage complexes] are also potent DNA lesions” (pmc.ncbi.nlm.nih.gov). This is poignantly true for TOP2B: it is required for normal transcription of many genes, yet the very breaks it creates can lead to mutations or chromosome translocations if misrepaired (pmc.ncbi.nlm.nih.gov). Recent high-profile studies underscore this fine line. For example, Canela et al. (2019) showed that TOP2B-induced DSBs in neural cells can accumulate when DNA damage response is impaired, possibly linking to neurodegeneration in ATM-deficient models (pubmed.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Papapietro and Nejentsev (2022) emphasized in a review that “in recent years, TOP2B emerged as one of the key proteins connecting transcription and 3D genome organization”, but also that “unresolved TOP2B activity at loop anchors can cause DNA translocations often seen in cancer” (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Their work on B cells brings a new appreciation for TOP2B’s specificity – as they put it, the discovery of B-cell developmental defects in TOP2B-deficient patients “highlights the fundamental and unique dependency” of certain cell lineages on DNA topology regulation (pmc.ncbi.nlm.nih.gov). In practical terms, this means genome topology isn’t just a background housekeeping task; it’s an active, regulated component of cell fate decisions.

Structurally, ongoing research is shedding light on how TOP2B works at the atomic level. Cryo-EM and crystallography studies in the last few years have resolved parts of human TOP2B in complex with DNA and inhibitors (www.nature.com). These structures reveal how TOP2B’s ATPase domains dimerize upon ATP binding, how the DNA gate opens/closes, and how the C-terminal region might interact with other proteins. Such insights are guiding the design of isoform-specific drugs and improved TOP2B inhibitors that avoid trapping the cleavage complex (to act as catalytic inhibitors rather than poisons) (pmc.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). For instance, structural differences in the C-terminal domain are being explored as a route to selectively target TOP2B versus TOP2A (pmc.ncbi.nlm.nih.gov).

Another active research area is mapping TOP2B’s genome-wide binding and its relationship to epigenetic features. High-resolution ChIP-seq and CUT&Tag profiles of TOP2B have been integrated with maps of R-loops, G-quadruplexes, and enhancer-promoter contacts to see where TOP2B is most needed (www.sciencedirect.com) (pmc.ncbi.nlm.nih.gov). One finding is that TOP2B often colocalizes with sites of active transcription and overlaps with RNAP II and BRD4 peaks, especially on long genes, suggesting a role in preventing R-loop accumulation and transcription-associated recombination. Additionally, cancer genome sequencing projects have identified mutation clusters near TOP2B binding motifs in certain non-coding regions, implying TOP2B may inadvertently contribute to localized mutational processes (by cleavage at specific hotspots) (www.nature.com) (pmc.ncbi.nlm.nih.gov).

In summary, current expert consensus portrays TOP2B as a crucial DNA enzyme with specialized roles in gene regulation. It acts as a molecular “untangler” that not only prevents topological problems but also actively participates in gene control by coupling with transcription and chromatin factors. “Topoisomerases introduce transient DNA breaks to relax supercoiled DNA, remove catenanes and enable chromosome segregation,” wrote Pommier et al. (2016) in Nature Reviews (www.nature.com) – and TOP2B exemplifies this, with the added twist that it is harnessed for developmental gene expression. As our understanding deepens (through 2023 and 2024 studies on immune cells, aging, and genome architecture), TOP2B stands out not just as a maintenance enzyme but as a dynamic regulator at the heart of nuclear function. Its activity is a double-edged sword: essential for normal physiology, yet a source of genomic fragility when misregulated. This duality makes TOP2B a fascinating subject of ongoing research, with implications ranging from fundamental biology to targeted therapies.

References: (Key references are cited inline above with publication year and source)

Citations

1. AnnotationURLCitation(end_index=447, start_index=309, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=%284%20%E2%80%93%208%29,of%20TOP2B%20in%20the%20immune')
2. AnnotationURLCitation(end_index=750, start_index=615, title='TOP2B Gene - GeneCards | TOP2B Protein | TOP2B Antibody', type='url_citation', url='https://www.genecards.org/cgi-bin/carddisp.pl?gene=TOP2B#:~:text=,cell%20differentiation.%20TOP2B_HUMAN%2CQ02880')
3. AnnotationURLCitation(end_index=1035, start_index=870, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=link%20between%20TOP2%20and%20the,terminal%20regions%20%28Figure%C2%A01B%29%20and')
4. AnnotationURLCitation(end_index=1165, start_index=1036, title='TOP2B Gene - GeneCards | TOP2B Protein | TOP2B Antibody', type='url_citation', url='https://www.genecards.org/cgi-bin/carddisp.pl?gene=TOP2B#:~:text=%2A%20Reaction%3DATP,TOP2B_HUMAN%2CQ02880')
5. AnnotationURLCitation(end_index=1419, start_index=1284, title='TOP2B Gene - GeneCards | TOP2B Protein | TOP2B Antibody', type='url_citation', url='https://www.genecards.org/cgi-bin/carddisp.pl?gene=TOP2B#:~:text=,cell%20differentiation.%20TOP2B_HUMAN%2CQ02880')
6. AnnotationURLCitation(end_index=1808, start_index=1670, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=%284%20%E2%80%93%208%29,of%20TOP2B%20in%20the%20immune')
7. AnnotationURLCitation(end_index=1979, start_index=1809, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=TOP2B%20structure%20and%20function,mediated%20DNA%20breaks%2C%20chromatin%20remodeling')
8. AnnotationURLCitation(end_index=2302, start_index=2132, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=TOP2B%20structure%20and%20function,mediated%20DNA%20breaks%2C%20chromatin%20remodeling')
9. AnnotationURLCitation(end_index=2590, start_index=2461, title='TOP2B Gene - GeneCards | TOP2B Protein | TOP2B Antibody', type='url_citation', url='https://www.genecards.org/cgi-bin/carddisp.pl?gene=TOP2B#:~:text=%2A%20Reaction%3DATP,TOP2B_HUMAN%2CQ02880')
10. AnnotationURLCitation(end_index=2870, start_index=2705, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=link%20between%20TOP2%20and%20the,terminal%20regions%20%28Figure%C2%A01B%29%20and')
11. AnnotationURLCitation(end_index=3000, start_index=2871, title='TOP2B Gene - GeneCards | TOP2B Protein | TOP2B Antibody', type='url_citation', url='https://www.genecards.org/cgi-bin/carddisp.pl?gene=TOP2B#:~:text=,treatment%20of%20human%20cancers%20TOP2B')
12. AnnotationURLCitation(end_index=3373, start_index=3238, title='TOP2B Gene - GeneCards | TOP2B Protein | TOP2B Antibody', type='url_citation', url='https://www.genecards.org/cgi-bin/carddisp.pl?gene=TOP2B#:~:text=,cell%20differentiation.%20TOP2B_HUMAN%2CQ02880')
13. AnnotationURLCitation(end_index=3716, start_index=3551, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=link%20between%20TOP2%20and%20the,terminal%20regions%20%28Figure%C2%A01B%29%20and')
14. AnnotationURLCitation(end_index=3887, start_index=3717, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=TOP2B%20structure%20and%20function,mediated%20DNA%20breaks%2C%20chromatin%20remodeling')
15. AnnotationURLCitation(end_index=4180, start_index=3999, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=transiently%20cleaving%20both%20strands%20of,encode%20two%20TOP2%20paralogues%2C%20topoisomerases')
16. AnnotationURLCitation(end_index=4442, start_index=4331, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=%281%20%29,TOP2B%20activity')
17. AnnotationURLCitation(end_index=4635, start_index=4524, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=%281%20%29,TOP2B%20activity')
18. AnnotationURLCitation(end_index=4942, start_index=4804, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=%284%20%E2%80%93%208%29,of%20TOP2B%20in%20the%20immune')
19. AnnotationURLCitation(end_index=5239, start_index=5101, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=%284%20%E2%80%93%208%29,of%20TOP2B%20in%20the%20immune')
20. AnnotationURLCitation(end_index=5405, start_index=5240, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=link%20between%20TOP2%20and%20the,terminal%20regions%20%28Figure%C2%A01B%29%20and')
21. AnnotationURLCitation(end_index=5628, start_index=5499, title='TOP2B Gene - GeneCards | TOP2B Protein | TOP2B Antibody', type='url_citation', url='https://www.genecards.org/cgi-bin/carddisp.pl?gene=TOP2B#:~:text=,treatment%20of%20human%20cancers%20TOP2B')
22. AnnotationURLCitation(end_index=5918, start_index=5780, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=%284%20%E2%80%93%208%29,of%20TOP2B%20in%20the%20immune')
23. AnnotationURLCitation(end_index=6073, start_index=5919, title='Role of topoisomerase IIbeta in the expression of developmentally regulated genes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/16923961/#:~:text=However%2C%20the%20expression%20of%20nearly,interacting%20protein%2C%20were')
24. AnnotationURLCitation(end_index=6367, start_index=6229, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=%284%20%E2%80%93%208%29,of%20TOP2B%20in%20the%20immune')
25. AnnotationURLCitation(end_index=6538, start_index=6368, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=TOP2B%20structure%20and%20function,mediated%20DNA%20breaks%2C%20chromatin%20remodeling')
26. AnnotationURLCitation(end_index=6928, start_index=6772, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=Elongation%20factors%20NELF%20and%20DSIF,resulting%20in%20a%20DNA%20loop')
27. AnnotationURLCitation(end_index=7099, start_index=6929, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=TOP2B%20structure%20and%20function,mediated%20DNA%20breaks%2C%20chromatin%20remodeling')
28. AnnotationURLCitation(end_index=7395, start_index=7257, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=%284%20%E2%80%93%208%29,of%20TOP2B%20in%20the%20immune')
29. AnnotationURLCitation(end_index=7847, start_index=7680, title='Role of topoisomerase IIbeta in the expression of developmentally regulated genes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/16923961/#:~:text=Mice%20lacking%20topoisomerase%20IIbeta%20,for%20the%20expression%20of%20developmentally')
30. AnnotationURLCitation(end_index=8015, start_index=7848, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=The%20description%20of%20the%20Top2b,of%20transcriptional%20programs%20far%20beyond')
31. AnnotationURLCitation(end_index=8541, start_index=8412, title='TOP2B Gene - GeneCards | TOP2B Protein | TOP2B Antibody', type='url_citation', url='https://www.genecards.org/cgi-bin/carddisp.pl?gene=TOP2B#:~:text=,treatment%20of%20human%20cancers%20TOP2B')
32. AnnotationURLCitation(end_index=8868, start_index=8701, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=The%20description%20of%20the%20Top2b,of%20transcriptional%20programs%20far%20beyond')
33. AnnotationURLCitation(end_index=9204, start_index=9037, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=The%20description%20of%20the%20Top2b,of%20transcriptional%20programs%20far%20beyond')
34. AnnotationURLCitation(end_index=9496, start_index=9335, title='Genome-wide prediction of topoisomerase IIβ binding by architectural factors and chromatin accessibility - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7845959/#:~:text=DNA%20topoisomerase%20II,predictions%2C%20with%20accessible%20chromatin%20and')
35. AnnotationURLCitation(end_index=9801, start_index=9617, title='Nuclear dynamics of topoisomerase IIβ reflects its catalytic activity that is regulated by binding of RNA to the C-terminal domain | Nucleic Acids Research | Oxford Academic', type='url_citation', url='https://academic.oup.com/nar/article/42/14/9005/1287871#:~:text=Nuclear%20dynamics%20of%20topoisomerase%20II%CE%B2,immunostaining%20varies%20depending%20on%20cell')
36. AnnotationURLCitation(end_index=10185, start_index=10024, title='Genome-wide prediction of topoisomerase IIβ binding by architectural factors and chromatin accessibility - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7845959/#:~:text=determine%20the%20genome,features%3A%20DNase%20I%20hypersensitivity%2C%20CTCF')
37. AnnotationURLCitation(end_index=10528, start_index=10367, title='Genome-wide prediction of topoisomerase IIβ binding by architectural factors and chromatin accessibility - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7845959/#:~:text=determine%20the%20genome,features%3A%20DNase%20I%20hypersensitivity%2C%20CTCF')
38. AnnotationURLCitation(end_index=10827, start_index=10666, title='Genome-wide prediction of topoisomerase IIβ binding by architectural factors and chromatin accessibility - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7845959/#:~:text=determine%20the%20genome,features%3A%20DNase%20I%20hypersensitivity%2C%20CTCF')
39. AnnotationURLCitation(end_index=11177, start_index=11076, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=%282%20%29,bottom')
40. AnnotationURLCitation(end_index=12033, start_index=11837, title='Targeting TOP2B as a vulnerability in aging and aging-related diseases - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/abs/pii/S0925443924000292#:~:text=evidence%20highlights%20the%20essential%20role,allowing%20proper%20progression%20of%20the')
41. AnnotationURLCitation(end_index=12364, start_index=12199, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=link%20between%20TOP2%20and%20the,terminal%20regions%20%28Figure%C2%A01B%29%20and')
42. AnnotationURLCitation(end_index=12799, start_index=12649, title='Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/28472494/#:~:text=Roles%20of%20the%20C,preserving%20the%20nuclear%20localization%20signal')
43. AnnotationURLCitation(end_index=13192, start_index=13060, title='Maternal topoisomerase II alpha, not topoisomerase II beta, enables embryonic development of zebrafish top2a-/- mutants - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3287258/#:~:text=Maternal%20topoisomerase%20II%20alpha%2C%20not,1')
44. AnnotationURLCitation(end_index=13960, start_index=13824, title='Genome Instability Induced by Topoisomerase Misfunction - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11477040/#:~:text=,growing%20repertoire%20of%20biological%20functions')
45. AnnotationURLCitation(end_index=14372, start_index=14200, title='Roles of eukaryotic topoisomerases in transcription, replication and genomic stability | Nature Reviews Molecular Cell Biology', type='url_citation', url='https://www.nature.com/articles/nrm.2016.111#:~:text=Topoisomerases%20introduce%20transient%20DNA%20breaks,the%20nuclear%20and%20mitochondrial%20genomes')
46. AnnotationURLCitation(end_index=14656, start_index=14485, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=Advances%20in%20genomic%20technologies%20have,in%20patients%20with%20TOP2B%20deficiency')
47. AnnotationURLCitation(end_index=14829, start_index=14657, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=key%20proteins%20connecting%20transcription%20and,mediated%20DNA%20topological%20changes')
48. AnnotationURLCitation(end_index=15373, start_index=15217, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=Elongation%20factors%20NELF%20and%20DSIF,resulting%20in%20a%20DNA%20loop')
49. AnnotationURLCitation(end_index=15763, start_index=15599, title='A critical role for topoisomerase IIb and DNA double strand breaks in transcription - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4984685/#:~:text=Recent%20studies%20have%20indicated%20a,breaks%20seemed%20both%20necessary%20and')
50. AnnotationURLCitation(end_index=16095, start_index=15931, title='A critical role for topoisomerase IIb and DNA double strand breaks in transcription - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4984685/#:~:text=Recent%20studies%20have%20indicated%20a,breaks%20seemed%20both%20necessary%20and')
51. AnnotationURLCitation(end_index=16514, start_index=16358, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=Elongation%20factors%20NELF%20and%20DSIF,resulting%20in%20a%20DNA%20loop')
52. AnnotationURLCitation(end_index=16930, start_index=16766, title='A critical role for topoisomerase IIb and DNA double strand breaks in transcription - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4984685/#:~:text=Recent%20studies%20have%20indicated%20a,breaks%20seemed%20both%20necessary%20and')
53. AnnotationURLCitation(end_index=17843, start_index=17742, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=%282%20%29,bottom')
54. AnnotationURLCitation(end_index=18293, start_index=18122, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=Advances%20in%20genomic%20technologies%20have,in%20patients%20with%20TOP2B%20deficiency')
55. AnnotationURLCitation(end_index=18466, start_index=18294, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=key%20proteins%20connecting%20transcription%20and,mediated%20DNA%20topological%20changes')
56. AnnotationURLCitation(end_index=18811, start_index=18710, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=%282%20%29,bottom')
57. AnnotationURLCitation(end_index=19140, start_index=18968, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=key%20proteins%20connecting%20transcription%20and,mediated%20DNA%20topological%20changes')
58. AnnotationURLCitation(end_index=19242, start_index=19141, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=%282%20%29,bottom')
59. AnnotationURLCitation(end_index=19695, start_index=19533, title='Topoisomerase IIb binding delineates localized mutational processes and driver mutations in cancer genomes | Nature Communications', type='url_citation', url='https://www.nature.com/articles/s41467-025-65005-6#:~:text=driver%20mutations%20in%20cancer%20genomes,a%20marker%20of%20mutational%20processes')
60. AnnotationURLCitation(end_index=19791, start_index=19696, title='Genome-wide prediction of topoisomerase IIβ binding by architectural factors and chromatin accessibility - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7845959/#:~:text=genome,used')
61. AnnotationURLCitation(end_index=20581, start_index=20414, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=The%20description%20of%20the%20Top2b,of%20transcriptional%20programs%20far%20beyond')
62. AnnotationURLCitation(end_index=20931, start_index=20764, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=The%20description%20of%20the%20Top2b,of%20transcriptional%20programs%20far%20beyond')
63. AnnotationURLCitation(end_index=21302, start_index=21170, title='Role of topoisomerase IIbeta in the expression of developmentally regulated genes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/16923961/#:~:text=a%20small%20number%20,interacting%20protein%2C%20were')
64. AnnotationURLCitation(end_index=21671, start_index=21539, title='Role of topoisomerase IIbeta in the expression of developmentally regulated genes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/16923961/#:~:text=a%20small%20number%20,interacting%20protein%2C%20were')
65. AnnotationURLCitation(end_index=21938, start_index=21779, title='Role of topoisomerase IIbeta in the expression of developmentally regulated genes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/16923961/#:~:text=affected%2C%20suggesting%20that%20TopIIbeta%20is,interacting%20protein%2C%20were')
66. AnnotationURLCitation(end_index=22262, start_index=22087, title='Role of topoisomerase IIbeta in the expression of developmentally regulated genes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/16923961/#:~:text=affected%2C%20suggesting%20that%20TopIIbeta%20is,sensitive%20gene%2C%20Kcnd2%2C%20revealed%20the')
67. AnnotationURLCitation(end_index=22761, start_index=22586, title='Role of topoisomerase IIbeta in the expression of developmentally regulated genes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/16923961/#:~:text=affected%2C%20suggesting%20that%20TopIIbeta%20is,sensitive%20gene%2C%20Kcnd2%2C%20revealed%20the')
68. AnnotationURLCitation(end_index=22988, start_index=22829, title='Role of topoisomerase IIbeta in the expression of developmentally regulated genes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/16923961/#:~:text=affected%2C%20suggesting%20that%20TopIIbeta%20is,interacting%20protein%2C%20were')
69. AnnotationURLCitation(end_index=23391, start_index=23231, title='Target genes of Topoisomerase IIβ regulate neuronal survival and are defined by their chromatin state - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/22474351/#:~:text=Target%20genes%20of%20Topoisomerase%20II%CE%B2,The%20y%20axis%20represents%20log2')
70. AnnotationURLCitation(end_index=23526, start_index=23392, title='Role of topoisomerase IIbeta in the expression of developmentally regulated genes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/16923961/#:~:text=genes%20,study%2C%20transcription%20profiles%20of%20the')
71. AnnotationURLCitation(end_index=23817, start_index=23671, title='Target genes of Topoisomerase IIβ regulate neuronal survival and are defined by their chromatin state - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/22474351/#:~:text=defined%20by%20their%20chromatin%20state,%28B%29%20PCR%20validation')
72. AnnotationURLCitation(end_index=24257, start_index=24125, title='Role of topoisomerase IIbeta in the expression of developmentally regulated genes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/16923961/#:~:text=a%20small%20number%20,interacting%20protein%2C%20were')
73. AnnotationURLCitation(end_index=24423, start_index=24258, title='Role of topoisomerase IIbeta in the expression of developmentally regulated genes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/16923961/#:~:text=Role%20of%20topoisomerase%20IIbeta%20in,study%2C%20transcription%20profiles%20of%20the')
74. AnnotationURLCitation(end_index=24966, start_index=24800, title='Mutations in topoisomerase IIβ result in a B cell immunodeficiency - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6692411/#:~:text=Sequencing%20of%20patients%20with%20B,function%20in%20response%20to%20immunization')
75. AnnotationURLCitation(end_index=25323, start_index=25178, title='Mutations in topoisomerase IIβ result in a B cell immunodeficiency - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6692411/#:~:text=severe%20hypogammaglobulinemia%2C%20and%20absent%20CD19%2B,11')
76. AnnotationURLCitation(end_index=25479, start_index=25324, title='Mutations in topoisomerase IIβ result in a B cell immunodeficiency - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6692411/#:~:text=Affected%20patients%20have%20a%20normal,but%20may%20not%20be%20entirely')
77. AnnotationURLCitation(end_index=25731, start_index=25586, title='Mutations in topoisomerase IIβ result in a B cell immunodeficiency - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6692411/#:~:text=severe%20hypogammaglobulinemia%2C%20and%20absent%20CD19%2B,11')
78. AnnotationURLCitation(end_index=25887, start_index=25732, title='Mutations in topoisomerase IIβ result in a B cell immunodeficiency - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6692411/#:~:text=Affected%20patients%20have%20a%20normal,but%20may%20not%20be%20entirely')
79. AnnotationURLCitation(end_index=26211, start_index=26053, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=and%20contribute%20to%20DNA%20loops,mediated%20DNA%20topological%20changes')
80. AnnotationURLCitation(end_index=26584, start_index=26458, title='Mutations in topoisomerase IIβ result in a B cell immunodeficiency - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6692411/#:~:text=Top2b%5E%7B%E2%88%92%2F%E2%88%92%7Dmb1,cre')
81. AnnotationURLCitation(end_index=26677, start_index=26585, title='Mutations in topoisomerase IIβ result in a B cell immunodeficiency - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6692411/#:~:text=mb1,CD19')
82. AnnotationURLCitation(end_index=26986, start_index=26838, title='Mutations in topoisomerase IIβ result in a B cell immunodeficiency - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6692411/#:~:text=B%20cells%20fail%20to%20activate,in%20the%20absence%20of%20Top2b')
83. AnnotationURLCitation(end_index=27141, start_index=26987, title='Mutations in topoisomerase IIβ result in a B cell immunodeficiency - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6692411/#:~:text=Kruskal%E2%80%93Wallis%20test%29,Total%20number%20of%20CFSE%20positive')
84. AnnotationURLCitation(end_index=27686, start_index=27518, title='Mutations in topoisomerase IIβ result in a B cell immunodeficiency - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6692411/#:~:text=spleen%20and%20bone%20marrow%20%28Fig,Furthermore%2C%20expression%20of%20Pax5%2C%20a')
85. AnnotationURLCitation(end_index=28600, start_index=28434, title='Mutations in topoisomerase IIβ result in a B cell immunodeficiency - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6692411/#:~:text=Sequencing%20of%20patients%20with%20B,function%20in%20response%20to%20immunization')
86. AnnotationURLCitation(end_index=28759, start_index=28601, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=and%20contribute%20to%20DNA%20loops,mediated%20DNA%20topological%20changes')
87. AnnotationURLCitation(end_index=29086, start_index=28928, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=and%20contribute%20to%20DNA%20loops,mediated%20DNA%20topological%20changes')
88. AnnotationURLCitation(end_index=29796, start_index=29621, title='Reduction of DNA Topoisomerase Top2 Reprograms the Epigenetic Landscape and Extends Health and Life Span Across Species - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12151872/#:~:text=Reduction%20of%20DNA%20Topoisomerase%20Top2,via%20Inhibition%20of%20the%20PI3K%E2%80%90Akt')
89. AnnotationURLCitation(end_index=30210, start_index=30062, title='Ataxia telangiectasia mutated activation by transcription- and topoisomerase I-induced DNA double-strand breaks - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/19557000/#:~:text=Skip%20to%20main%20page%20content,mediator%20for%20the%20DNA%20damage')
90. AnnotationURLCitation(end_index=30974, start_index=30847, title='Topoisomerase IIb binding delineates localized mutational processes and driver mutations in cancer genomes | Nature Communications', type='url_citation', url='https://www.nature.com/articles/s41467-025-65005-6#:~:text=Type,for%20driver%20mutations%20and%20mutational')
91. AnnotationURLCitation(end_index=31281, start_index=31154, title='Topoisomerase IIb binding delineates localized mutational processes and driver mutations in cancer genomes | Nature Communications', type='url_citation', url='https://www.nature.com/articles/s41467-025-65005-6#:~:text=Type,for%20driver%20mutations%20and%20mutational')
92. AnnotationURLCitation(end_index=32064, start_index=31917, title='Catalytic Inhibitors of Topoisomerase II Differently Modulate the Toxicity of Anthracyclines in Cardiac and Cancer Cells - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3792022/#:~:text=Catalytic%20Inhibitors%20of%20Topoisomerase%20II,1%7D%2C%20Hana')
93. AnnotationURLCitation(end_index=32227, start_index=32065, title='Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/24116135/#:~:text=cardiotoxicity.%20Dexrazoxane%20%28ICRF,Its%20activity%20has%20traditionally%20been')
94. AnnotationURLCitation(end_index=32543, start_index=32420, title='Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/24116135/#:~:text=,Its%20activity%20has%20traditionally%20been')
95. AnnotationURLCitation(end_index=32713, start_index=32544, title='The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31773441/#:~:text=The%20Role%20of%20Topoisomerase%20II%CE%B2,catalytic%20inhibitor%20of%20topoisomerase%20II')
96. AnnotationURLCitation(end_index=33039, start_index=32869, title='The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31773441/#:~:text=concentration%20of%20dexrazoxane%20occurred%20slowly%2C,levels%20were%20at%20their%20lowest')
97. AnnotationURLCitation(end_index=33181, start_index=33040, title='The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31773441/#:~:text=occurring%20after%2024%20h,levels%20were%20at%20their%20lowest')
98. AnnotationURLCitation(end_index=33573, start_index=33403, title='The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31773441/#:~:text=concentration%20of%20dexrazoxane%20occurred%20slowly%2C,levels%20were%20at%20their%20lowest')
99. AnnotationURLCitation(end_index=33952, start_index=33829, title='Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/24116135/#:~:text=,Its%20activity%20has%20traditionally%20been')
100. AnnotationURLCitation(end_index=34122, start_index=33953, title='The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31773441/#:~:text=The%20Role%20of%20Topoisomerase%20II%CE%B2,catalytic%20inhibitor%20of%20topoisomerase%20II')
101. AnnotationURLCitation(end_index=34829, start_index=34657, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=key%20proteins%20connecting%20transcription%20and,mediated%20DNA%20topological%20changes')
102. AnnotationURLCitation(end_index=34931, start_index=34830, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=%282%20%29,bottom')
103. AnnotationURLCitation(end_index=35581, start_index=35439, title='Topobexin targets the Topoisomerase II ATPase domain for beta isoform-selective inhibition and anthracycline cardioprotection - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/40425539/#:~:text=Topobexin%20targets%20the%20Topoisomerase%20II,cancer%20effects')
104. AnnotationURLCitation(end_index=35752, start_index=35582, title='Topobexin targets the Topoisomerase II ATPase domain for beta isoform-selective inhibition and anthracycline cardioprotection - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12116762/#:~:text=Skip%20to%20main%20content%20Nat,and%20License%20information%20PMCID%3A%20PMC12116762')
105. AnnotationURLCitation(end_index=36092, start_index=35922, title='Topobexin targets the Topoisomerase II ATPase domain for beta isoform-selective inhibition and anthracycline cardioprotection - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12116762/#:~:text=Skip%20to%20main%20content%20Nat,and%20License%20information%20PMCID%3A%20PMC12116762')
106. AnnotationURLCitation(end_index=36455, start_index=36285, title='Topobexin targets the Topoisomerase II ATPase domain for beta isoform-selective inhibition and anthracycline cardioprotection - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12116762/#:~:text=Skip%20to%20main%20content%20Nat,and%20License%20information%20PMCID%3A%20PMC12116762')
107. AnnotationURLCitation(end_index=37284, start_index=37116, title='Targeting TOP2B as a vulnerability in aging and aging-related diseases - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/abs/pii/S0925443924000292#:~:text=Targeting%20TOP2B%20as%20a%20vulnerability,related%20diseases')
108. AnnotationURLCitation(end_index=37646, start_index=37471, title='Reduction of DNA Topoisomerase Top2 Reprograms the Epigenetic Landscape and Extends Health and Life Span Across Species - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12151872/#:~:text=Reduction%20of%20DNA%20Topoisomerase%20Top2,via%20Inhibition%20of%20the%20PI3K%E2%80%90Akt')
109. AnnotationURLCitation(end_index=38614, start_index=38452, title='Topoisomerase IIb binding delineates localized mutational processes and driver mutations in cancer genomes | Nature Communications', type='url_citation', url='https://www.nature.com/articles/s41467-025-65005-6#:~:text=driver%20mutations%20in%20cancer%20genomes,a%20marker%20of%20mutational%20processes')
110. AnnotationURLCitation(end_index=38984, start_index=38812, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=key%20proteins%20connecting%20transcription%20and,mediated%20DNA%20topological%20changes')
111. AnnotationURLCitation(end_index=39365, start_index=39178, title='Genome Instability Induced by Topoisomerase Misfunction - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11477040/#:~:text=Genome%20Instability%20Induced%20by%20Topoisomerase,growing%20repertoire%20of%20biological%20functions')
112. AnnotationURLCitation(end_index=39726, start_index=39554, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=key%20proteins%20connecting%20transcription%20and,mediated%20DNA%20topological%20changes')
113. AnnotationURLCitation(end_index=40147, start_index=39981, title='Ataxia telangiectasia mutated activation by transcription- and topoisomerase I-induced DNA double-strand breaks - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/19557000/#:~:text=Ataxia%20telangiectasia%20mutated%20activation%20by,mediator%20for%20the%20DNA%20damage')
114. AnnotationURLCitation(end_index=40282, start_index=40148, title='Endogenous topoisomerase II-mediated DNA breaks drive thymic cancer predisposition linked to ATM deficiency - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7021672/#:~:text=%28T,malignancies%20are%20frequently%20linked%20to')
115. AnnotationURLCitation(end_index=40741, start_index=40569, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=key%20proteins%20connecting%20transcription%20and,mediated%20DNA%20topological%20changes')
116. AnnotationURLCitation(end_index=40843, start_index=40742, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=%282%20%29,bottom')
117. AnnotationURLCitation(end_index=41272, start_index=41114, title='Topoisomerase 2β and DNA topology during B cell development - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/#:~:text=and%20contribute%20to%20DNA%20loops,mediated%20DNA%20topological%20changes')
118. AnnotationURLCitation(end_index=41844, start_index=41642, title='Topobexin targets the Topoisomerase II ATPase domain for beta isoform-selective inhibition and anthracycline cardioprotection | Nature Communications', type='url_citation', url='https://www.nature.com/articles/s41467-025-60167-9#:~:text=selective%20inhibition%20and%20anthracycline%20cardioprotection,redundant%20cellular%20functions.%20Anthracyclines%20induce')
119. AnnotationURLCitation(end_index=42359, start_index=42212, title='Catalytic Inhibitors of Topoisomerase II Differently Modulate the Toxicity of Anthracyclines in Cardiac and Cancer Cells - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3792022/#:~:text=Catalytic%20Inhibitors%20of%20Topoisomerase%20II,1%7D%2C%20Hana')
120. AnnotationURLCitation(end_index=42531, start_index=42360, title='Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/24116135/#:~:text=Catalytic%20inhibitors%20of%20topoisomerase%20II,Its%20activity%20has%20traditionally%20been')
121. AnnotationURLCitation(end_index=42836, start_index=42666, title='Topobexin targets the Topoisomerase II ATPase domain for beta isoform-selective inhibition and anthracycline cardioprotection - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12116762/#:~:text=Skip%20to%20main%20content%20Nat,and%20License%20information%20PMCID%3A%20PMC12116762')
122. AnnotationURLCitation(end_index=43300, start_index=43132, title='Targeting TOP2B as a vulnerability in aging and aging-related diseases - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/abs/pii/S0925443924000292#:~:text=Targeting%20TOP2B%20as%20a%20vulnerability,related%20diseases')
123. AnnotationURLCitation(end_index=43462, start_index=43301, title='Genome-wide prediction of topoisomerase IIβ binding by architectural factors and chromatin accessibility - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7845959/#:~:text=DNA%20topoisomerase%20II,predictions%2C%20with%20accessible%20chromatin%20and')
124. AnnotationURLCitation(end_index=44121, start_index=43959, title='Topoisomerase IIb binding delineates localized mutational processes and driver mutations in cancer genomes | Nature Communications', type='url_citation', url='https://www.nature.com/articles/s41467-025-65005-6#:~:text=driver%20mutations%20in%20cancer%20genomes,a%20marker%20of%20mutational%20processes')
125. AnnotationURLCitation(end_index=44217, start_index=44122, title='Genome-wide prediction of topoisomerase IIβ binding by architectural factors and chromatin accessibility - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7845959/#:~:text=genome,used')
126. AnnotationURLCitation(end_index=44874, start_index=44702, title='Roles of eukaryotic topoisomerases in transcription, replication and genomic stability | Nature Reviews Molecular Cell Biology', type='url_citation', url='https://www.nature.com/articles/nrm.2016.111#:~:text=Topoisomerases%20introduce%20transient%20DNA%20breaks,the%20nuclear%20and%20mitochondrial%20genomes')

The user is asking me to research the gene TOP2B (UniProt Q02880), which encodes DNA topoisomerase 2-beta in humans. Let me verify that this is the correct gene based on the provided information:

• UniProt Accession: Q02880
• Protein Description: DNA topoisomerase 2-beta
• Gene Name: TOP2B
• Organism: Homo sapiens
• Protein Family: Type II topoisomerase family
• Key Domains: DNA_Topoisomerase_II, DTHCT, HATPase_C_sf, etc.

Now looking at my search results, I have extensive information about TOP2B that matches this description. The search results contain:
- Multiple Wikipedia articles about TOP2B
- Biochemical and structural information about TOP2B function
- Information about TOP2B's roles in transcription, neuronal activity, B cell development
- Information about TOP2B interactions with DNA and other proteins
- Information about mutations in TOP2B
- Recently published research (2024-2025) on TOP2B

This is definitely the correct gene. Now I need to write a comprehensive research report covering:
1. Primary function - what reaction is catalyzed, substrate specificity
2. Localization - where in/outside the cell it functions
3. Signaling/biochemical pathways
4. Recent developments and current understanding

I should aim for 10,000+ words and maintain an academic tone with proper citations from the search results.

Key topics to cover:
- Basic enzymatic function (DNA topoisomerase II activity)
- Mechanism of action (transient DSBs, strand passage)
- Cellular localization (nucleoplasm, nucleolus)
- Expression patterns (ubiquitous, especially in non-dividing cells)
- Role in transcription
- Role in DNA topology and chromatin architecture
- Role in neuronal development and function
- Role in B cell development
- Role in immediate early gene activation

• Interactions with other proteins (CTCF, cohesin, PARP, ZATT/ZNF451, etc.)
• Clinical significance and drug targeting
• Recent structural and mechanistic insights
• Regulation (ATP-dependent, phosphorylation, etc.)

I'll explore the protein's complex network of interactions and regulatory mechanisms. The research will delve into how TOP2B interacts with critical cellular proteins like CTCF and cohesin, examining its role in chromatin organization and gene regulation. I'll investigate its clinical implications, focusing on potential therapeutic targeting and its significance in various cellular processes. The structural insights and regulatory nuances will provide a comprehensive understanding of this essential enzyme's multifaceted functions.

DNA Topoisomerase II-Beta (TOP2B): Molecular Function, Cellular Roles, and Biological Significance

DNA topoisomerase II-beta (TOP2B) is a ubiquitously expressed nuclear enzyme that catalyzes reversible double-strand breaks in DNA to resolve topological constraints arising from essential cellular processes including transcription, DNA replication, and chromatin organization.[1][2][3] Unlike its paralog TOP2A, which is primarily expressed during S and G2 cell cycle phases in proliferating cells, TOP2B is constitutively expressed throughout the cell cycle in both dividing and non-dividing cells, conferring upon it distinct and specialized functions in maintaining genomic integrity and regulating gene expression programs, particularly in postmitotic neurons and during early B cell development.[1][7][9] The enzyme functions through a two-gate mechanism that introduces transient double-strand breaks protected by covalent protein-DNA intermediates, allowing strand passage and subsequent religation—a reaction that is essential yet paradoxically generates opportunities for genomic instability if not carefully regulated.[6][13] Recent discoveries have revealed that TOP2B mediates signal-dependent transcriptional activation, maintains three-dimensional genome organization through interactions with architectural proteins, and plays a critical role in neuronal learning and memory through activity-regulated double-strand break formation at immediate early genes.[1][2][7][11]

Basic Enzymatic Function and Molecular Mechanism

Catalytic Activity and Reaction Mechanism

TOP2B belongs to the type II topoisomerase family, a group of evolutionary conserved enzymes that catalyze topological changes in DNA by introducing transient double-strand breaks.[1][3][13] The fundamental problem that TOP2B solves is the accumulation of topological tension in DNA that arises from essential processes such as transcription and DNA replication. As RNA polymerase II and other DNA-dependent enzymes progress along the DNA template, they generate positive supercoiling ahead of the enzyme and negative supercoiling behind, creating torsional stress that impedes further progression if left unresolved.[44][47] TOP2B alleviates this topological constraint through a sophisticated two-gate mechanism that remains largely conserved from bacteria to humans.[13][16]

The reaction catalyzed by TOP2B proceeds through several discrete steps that together constitute the complete catalytic cycle.[3][13][16] First, the enzyme binds to DNA as a homodimer, with each monomer of the dimer responsible for cleaving one strand of the duplex DNA. At the catalytic site, a highly conserved tyrosine residue acts as a nucleophile to attack the DNA phosphodiester backbone, forming a covalent phosphotyrosyl linkage between the enzyme's tyrosine and the 5' phosphate end of the cleaved DNA.[3][31][35] This creates what is termed a TOP2-DNA cleavage complex (TOP2cc), in which the enzyme remains covalently attached to both DNA strands at the site of the break. Critically, the phosphotyrosyl bonds formed during cleavage protect the DNA ends from recognition by cellular DNA damage response machinery, preventing inappropriate activation of repair pathways that would normally respond to double-strand breaks.[3][28][31]

Following cleavage, an intact double-stranded DNA segment (the T-segment) passes through the transient break created by TOP2B, allowing the enzyme to alter the linking number of DNA and thus change its topological state.[3][13][16] The passage of the T-segment through the break is mediated by conformational changes in the enzyme that open both the N-gate (which binds and hydrolyzes ATP) and the C-gate (through which the T-segment exits).[13][16][31] After strand passage is complete, TOP2B rapidly reseals the break through an intrinsic ligation activity, in which the 3'-hydroxyl group of the DNA attacks the phosphotyrosyl bond to reform the intact phosphodiester backbone and regenerate native DNA.[3][13][16] Upon successful ligation, TOP2B dissociates from the DNA, completing one catalytic cycle.

The ATP hydrolysis catalyzed by the N-terminal ATPase domain of TOP2B is essential for the conformational changes required for strand passage but is not directly involved in DNA cleavage or ligation.[3][13][35] Rather, ATP binding and hydrolysis drive the enzyme through its catalytic cycle by promoting the conformational rearrangements necessary for opening the N-gate, allowing DNA binding and strand passage, and then closing the gates to stabilize the cleaved complex before ligation.[3][35] Recent structural studies have identified conserved catalytic residues in TOP2B's ATPase domain, including glutamic acid 103 (E103), which acts as the catalytic base for ATP hydrolysis, and key residues in the QTK loop that undergo conformational changes during the transition from ATP-bound to ADP-bound states.[32]

Substrate Specificity and Reaction Products

TOP2B exhibits relatively low sequence specificity for its DNA substrates compared to other DNA-binding proteins, suggesting that the enzyme recognizes more general structural features of DNA rather than specific nucleotide sequences.[3][13] However, accumulated evidence indicates that TOP2B shows a preference for certain genomic contexts. In particular, TOP2B accumulates at actively transcribed genes, enhancer regions, and promoters marked by histone modifications characteristic of active chromatin such as dimethylation of histone H3 at lysine 4 (H3K4me2).[7][11][22][25] Additionally, TOP2B is enriched at topologically associating domain (TAD) boundaries, where it colocalizes with CTCF and cohesin proteins that organize chromatin into three-dimensional structures.[12][23][25][37][40][43]

The primary reaction products generated by TOP2B catalysis are the resolution of DNA supercoiling and the decatenation of interlocked DNA molecules, in addition to the facilitation of transcription by removing topological barriers to RNA polymerase elongation.[1][3][13] When TOP2B acts on positively supercoiled DNA, it introduces a transient break that allows the DNA to rotate and relieve the supercoiling tension, converting the overwound DNA to a relaxed state.[3] Similarly, when acting on negatively supercoiled DNA, TOP2B can change the linking number to adjust the degree of supercoiling. The enzyme can also act on catenated DNA molecules (interlinked circles of DNA) that frequently form as byproducts of DNA replication and transcription, using its enzymatic activity to separate these interlocked structures through its strand passage mechanism.[3][13]

Cellular Localization and Subcellular Distribution

Nuclear Compartmentalization

TOP2B is primarily a nuclear protein that localizes to the nucleoplasm under normal cellular conditions, where the vast majority of its catalytic activity occurs in association with transcriptionally active chromatin.[3][9][34] However, the enzyme exhibits dynamic and regulated movement between the nucleoplasm and the nucleolus, a subnuclear compartment enriched in ribosomal RNA (rRNA) synthesis machinery.[3][9] This regulated nucleolar-nucleoplasmic shuttling is controlled by the cellular energy status, particularly the levels of adenosine triphosphate (ATP).[9][34] When ATP levels are depleted through pharmacological means (using 2-deoxyglucose and oligomycin to inhibit ATP synthesis) or through mild detergent treatment that causes extracellular ATP leakage, TOP2B rapidly accumulates in the nucleolus, shifting from a catalytically active form in the nucleoplasm to a quiescent form sequestered in the nucleolus.[3][9][34] Conversely, restoration of normal cellular ATP levels causes TOP2B to rapidly relocate from the nucleolus back to the nucleoplasm, where it resumes its catalytic activity.[9][34]

This ATP-dependent subcellular localization represents a sophisticated regulatory mechanism that allows cells to downregulate TOP2B activity during periods of energy stress. The molecular basis for ATP-dependent nucleolar localization involves a specific 50-residue region in the C-terminal domain of TOP2B termed the catalytic requirement domain (CRD).[3][34] This domain mediates the interaction between TOP2B and cellular RNA, and this RNA-binding activity is essential for the nucleolar targeting of the enzyme.[3][34] Isolated RNA inhibits the catalytic activity of TOP2B through direct interaction with the CRD domain, providing a mechanism by which RNA abundance in the nucleolus can regulate enzyme activity.[3][34] The preference of TOP2B for binding to poly(A)- negative RNA (such as ribosomal RNA) over poly(A)-positive messenger RNA indicates selectivity in the interactions that govern nucleolar accumulation.[3][34]

Interaction with Chromatin and Regulatory Elements

TOP2B binds preferentially to promoters and enhancers of actively transcribed genes, where its occupancy correlates strongly with the presence of H3K4me2 and other active chromatin marks.[7][22][24][25] Genome-wide mapping studies using chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-seq) reveal that TOP2B enrichment at promoters is approximately five-fold higher than at exons, introns, or intergenic regions, indicating strong preferential targeting to these regulatory elements.[7][24] Furthermore, TOP2B is present at approximately 50% of CTCF and cohesin binding sites at TAD boundaries, particularly at the anchors of chromatin loops conserved across multiple cell types and species.[37][40][43] This preferential localization to genomic sites associated with chromatin organization suggests that TOP2B plays a direct role in maintaining the three-dimensional structure of the genome.

The colocalization of TOP2B with CTCF and cohesin at TAD boundaries may facilitate the resolution of topological stress generated during chromatin loop extrusion, a process mediated by cohesin complexes that extrude chromatin to form the characteristic loops that characterize TADs.[12][35][37][40][43] As cohesin moves along the chromatin fiber, it generates accumulation of positive supercoiling ahead of the complex and negative supercoiling behind it. TOP2B positioned at TAD boundaries can relieve this transcription-induced supercoiling, allowing cohesin to continue its loop extrusion activity and stabilizing the three-dimensional organization of the genome.[35][37][40][43][44] This function is particularly important during rapid transcription at developmentally regulated genes and in response to acute transcriptional stimulation by extracellular signals.[19][22][25]

Primary Functions in Gene Regulation and Transcription

Role in Signal-Dependent Transcriptional Activation

One of the most significant discoveries regarding TOP2B function is its essential role in enabling the rapid transcriptional activation of immediate early genes (IEGs) in response to extracellular signals including growth factors, hormones, and neuronal stimulation.[2][7][11][22][25][28] IEGs are a set of genes whose expression is rapidly induced in response to cellular stimulation, typically reaching peak expression within minutes, and whose protein products include transcription factors that control the expression of hundreds of downstream target genes.[2][7][11] Examples of classical IEGs include c-fos, c-jun, egr1, and early response genes induced by estrogen receptor activation.[2][22][25][48]

The mechanism by which TOP2B facilitates rapid IEG activation involves its ability to release paused RNA polymerase II that has accumulated at promoter-proximal regions of these genes.[7][11][22][25][28] Many IEGs are regulated by a mechanism called promoter-proximal pausing, in which RNA polymerase II is recruited to the promoter and initiates transcription but then pauses at a distance of 30-60 nucleotides downstream of the transcription start site.[7][11][22][25] This pausing is maintained by negative elongation factors such as DSIF and NELF that bind to the polymerase and prevent productive elongation.[7][11][22] Upon receipt of an appropriate signal, such as binding of a ligand to a nuclear hormone receptor, these elongation factors are phosphorylated and released, allowing RNA polymerase II to escape the pause site and proceed with elongation.[7][11][22][25]

TOP2B contributes to this pause release mechanism through its catalytic activity to resolve positive supercoiling that accumulates in the DNA region immediately ahead of the paused polymerase.[7][11][22][25][28][44] As RNA polymerase II initiates transcription and begins to unwind the DNA helix within the promoter region, positive supercoiling accumulates in the DNA ahead of the transcription bubble.[44] This topological stress can physically impede the forward progression of the polymerase and maintain it in the paused state.[7][11][22][25][28] TOP2B, recruited to the promoter through interactions with transcription factors and other regulatory proteins, introduces transient double-strand breaks that allow the accumulation of positive supercoiling to be relieved, thereby removing a physical barrier to polymerase elongation.[7][11][22][25][28]

Importantly, TOP2B-mediated transcriptional activation of IEGs is accompanied by and functionally linked to the formation of double-strand breaks at the promoters of these genes.[7][11][22][25][48] These breaks are transient in nature and are rapidly repaired through the non-homologous end joining (NHEJ) pathway, typically within 15 minutes to 2 hours following their formation.[1][11][22][25] The recruitment of NHEJ factors including DNA-dependent protein kinase catalytic subunit (DNA-PKcs), KU70, KU80, and DNA ligase IV to the promoters of activated IEGs suggests that these DNA repair factors participate in the transcriptional activation process rather than simply repairing accidental DNA damage.[1][11][22][25][26] This intriguing observation has led to the hypothesis that NHEJ factors may actively participate in transcription regulation, perhaps through chromatin remodeling or through recruitment of additional transcriptional regulators to sites of TOP2B-mediated breaks.[11][22][25][26]

Recent evidence indicates that TOP2B activity during transcriptional activation is regulated by posttranslational modifications and by kinase signaling cascades.[48] For example, the mitogen-activated protein kinase ERK2 has been shown to phosphorylate TOP2B at specific sites, and this phosphorylation enhances the recruitment of TOP2B to the promoters of IEGs and promotes its catalytic activity for DNA cleavage.[48] This direct phosphorylation of TOP2B by ERK2 provides a mechanistic link between growth factor signaling through the ERK pathway and the rapid activation of IEGs, ensuring that transcriptional responses are coordinated with extracellular signals.[48]

TOP2B in Transcription of Long Genes and Gene Length-Dependent Effects

A particularly striking feature of TOP2B function is its disproportionate importance in the transcription of long genes, particularly those exceeding 100 kilobases in length.[10][12][23][25] Many developmentally important genes and genes involved in neuronal function are exceptionally long, spanning distances of several hundred kilobases or even multiple megabases.[10][12][23][25] The transcription of such long genes presents unique topological challenges because the accumulation of supercoiling over the lengthy transcribed region can create formidable barriers to polymerase elongation.[10][12][23][25][35] TOP2B appears to be particularly critical for removing the torsional stress generated during transcription of these long genes, allowing RNA polymerase II to progress efficiently from the promoter through the gene body to the termination region.[10][12][23][25][35]

The gene length-dependency of TOP2B function has been elegantly demonstrated through comparative studies of TOP2B-dependent and TOP2B-independent genes in various cell types and developmental contexts.[10][12][25] In neuronal cells, where TOP2B expression is particularly high, genes involved in neurogenesis and neuronal function that exceed 100 kilobases are predominantly affected by TOP2B depletion or inhibition, whereas shorter genes show minimal transcriptional changes.[10][12][25] This finding suggests that the necessity for TOP2B activity in transcription elongation increases dramatically with gene length, likely reflecting the proportional increase in topological stress generated during transcription of longer templates.[10][12][25][35]

The unique importance of TOP2B for long gene transcription has profound implications for developmental biology and disease, because many genes essential for cellular differentiation and tissue-specific functions are exceptionally long.[10][12][23][25] This gene length dependency may explain the tissue-specific phenotypes observed in TOP2B deficiency disorders, wherein certain cell lineages show severe developmental defects while others are relatively spared.[10][12][23][25]

TOP2B in Neuronal Development and Function

Expression Pattern in Neural Tissue

A fundamental developmental switch occurs during neuronal differentiation wherein cells downregulate expression of TOP2A and upregulate expression of TOP2B.[7][10] In neural progenitor cells actively engaged in cell division, TOP2A is the predominant topoisomerase II isoform, reflecting the requirement for TOP2A in DNA replication and chromosome segregation during S phase and mitosis.[7][10][33] However, as neuronal progenitor cells differentiate into postmitotic neurons and exit the cell cycle, there is a dramatic shift in expression such that TOP2B becomes the primary topoisomerase II isoform present in these cells, while TOP2A expression declines to nearly undetectable levels.[7][10][33]

This developmental switch in topoisomerase II isoforms reflects the changing demands on topoisomerase II function during the transition from proliferative neural progenitors to postmitotic, functionally mature neurons.[7][10][33] The continued expression of TOP2B in postmitotic neurons, despite the cessation of DNA replication, indicates that TOP2B performs essential functions in non-dividing cells that are independent of replication.[7][10][33] Indeed, in fetal human telencephalon during early corticogenesis (9-12 postconceptional weeks), TOP2B is expressed in both proliferative zones (the ventricular zone and subventricular zone containing dividing neural progenitors) and in the postmitotic compartments (the intermediate zone and cortical plate containing differentiating and mature neurons), whereas TOP2A expression is restricted to proliferative zones.[33]

Role in Neuronal Survival and Developmental Gene Expression

The critical importance of TOP2B for neuronal survival is demonstrated by the severe phenotype of TOP2B knockout mice, which die during embryonic or early postnatal development with severe neurological abnormalities.[7][10] Detailed analysis of TOP2B-deficient neurons reveals that loss of TOP2B protein or its catalytic activity leads to premature death of postmitotic neurons, occurring several days after differentiation from neuronal progenitors.[7][10] This neuronal degeneration is not accompanied by obvious changes in the differentiation process itself—stem cell properties and the early steps of neuronal differentiation proceed normally—but rather emerges specifically in postmitotic neurons, indicating that TOP2B has a specific role in maintaining the survival of differentiated neurons.[7][10]

Genome-wide binding studies using chromatin immunoprecipitation reveal that TOP2B occupies promoters of genes specifically expressed during neuronal differentiation and in mature neurons, with particularly high enrichment at promoters of genes containing active histone modifications such as H3K4me2 and H3K4me3.[7][24] These TOP2B target genes are preferentially involved in neuronal differentiation, neurogenesis, and neuronal function.[7][24] Strikingly, the absence of functional TOP2B leads to profound changes in the transcription of these neuronal genes, with many showing dramatically reduced expression in TOP2B-deficient neurons compared to wild-type controls.[7][24]

One particularly important TOP2B target gene is Ngfr, which encodes the neurotrophin receptor p75.[7][10] This receptor is normally repressed in differentiated neurons through the binding and activity of TOP2B at its promoter region.[7][10] In the absence of TOP2B, Ngfr expression is dramatically upregulated in differentiated neurons, and this aberrant upregulation of p75 signaling appears to trigger apoptotic pathways that lead to neuronal death.[7][10] The upregulation of p75 in TOP2B-deficient neurons suggests a model in which TOP2B maintains neuronal survival through active repression of pro-apoptotic signaling pathways, ensuring that differentiated neurons do not receive death signals through p75 receptor activation.[7][10]

TOP2B-Mediated DSBs in Learning and Memory

A remarkable discovery in neurobiology is that neuronal activity itself triggers the formation of TOP2B-mediated double-strand breaks at the promoters of immediate early genes involved in learning and memory.[1][7][11][55][58] During associative learning paradigms such as fear conditioning, wherein animals learn to associate a neutral stimulus (like a context) with an aversive stimulus (a foot shock), TOP2B is rapidly recruited to the promoters of numerous immediate early genes, where it generates transient double-strand breaks.[1][7][11][55][58] These learning-induced DSBs occur throughout the genome, with hundreds detected in brain regions critical for learning such as the medial prefrontal cortex and hippocampus.[55]

The formation of these activity-induced DSBs is essential for the transcriptional response to learning, as demonstrated by studies in which TOP2B activity is inhibited or TOP2B expression is reduced.[1][7][11][55] Under these conditions, the formation of learning-induced DSBs is dramatically attenuated, and the transcriptional response to learning is severely impaired, indicating that TOP2B-mediated DSBs are functionally required for learning-dependent gene expression.[1][7][11][55] Furthermore, the location and timing of TOP2B-mediated DSBs correlate precisely with the induction of immediate early genes following learning experiences.[55]

The precise neuronal and molecular mechanisms that link neuronal activity during learning to TOP2B recruitment and activation involve calcium signaling and phosphatase activity.[58] Neuronal stimulation triggers influx of calcium through N-methyl-D-aspartate (NMDA) receptors, which activates the calcium-dependent phosphatase calcineurin.[58] Activated calcineurin associates with TOP2B and dephosphorylates it at specific serine residues (S1509 and S1511), thereby stimulating the DNA cleavage activity of TOP2B and promoting the formation of activity-induced DSBs at promoters of early response genes.[58] This calcineurin-mediated dephosphorylation of TOP2B occurs specifically at the nuclear periphery, where genes that respond to neuronal activity appear to preferentially localize, providing spatial organization to the coupling between neuronal activity and transcriptional regulation.[58]

The double-strand breaks formed by TOP2B during learning are rapidly repaired through the NHEJ pathway, typically within 15 minutes to 2 hours, and this repair process appears to be functionally coupled to chromatin modifications and transcription initiation.[1][11][55] Notably, the repair of TOP2B-mediated DSBs at immediate early gene promoters is accompanied by DNA demethylation of the promoter region, which facilitates the opening of chromatin and allows transcription factor access to the promoter, ultimately enabling robust transcription of the learning-induced genes.[1]

TOP2B in B Cell Development and Immunodeficiency

Discovery of TOP2B Mutations in B Cell Immunodeficiency

A major breakthrough in understanding TOP2B function came from the discovery of heterozygous mutations in TOP2B in patients with a rare form of B cell immunodeficiency characterized by absent peripheral B cells combined with dysmorphic features, which has been termed TOP2B immunodeficiency with limb abnormalities and uroepithelial defects (BILU syndrome) or Hoffman syndrome.[12][20][23][25][46] These patients present with a specific developmental block at an early stage of B cell development: CD19+ B cell precursors are entirely absent from their bone marrow, while T cells develop normally, suggesting a cell-lineage-specific requirement for TOP2B in B cells.[12][20][23][25][46]

The mutations identified in TOP2B from immunodeficient patients include heterozygous dominant negative mutations that cluster in the TOPRIM domain and related catalytic domains of the enzyme.[20][46] Analysis of these mutations reveals that they substantially reduce the enzymatic activity of TOP2B, with activity reductions of more than 10-fold observed in biochemical assays using purified recombinant mutant TOP2B protein.[20][46] Importantly, coexpression of mutant and wild-type TOP2B protein reveals a dominant negative effect, wherein the mutant protein not only exhibits reduced intrinsic enzymatic activity but also inhibits the activity of wild-type TOP2B and TOP2A through formation of inactive enzyme complexes.[20][46] This dominant negative mechanism explains why heterozygous patients carrying a single mutant allele show severe B cell developmental defects, rather than the mild or absent phenotype expected from simple haploinsufficiency.[20][46]

B Cell-Specific Dependency on TOP2B

The discovery of B cell-specific defects caused by TOP2B mutations is particularly intriguing given that TOP2B is ubiquitously expressed in virtually all cell types, yet only B cells show developmental defects in TOP2B-deficient individuals and animal models.[12][20][23][25][46] This B cell-specific vulnerability to TOP2B deficiency appears to reflect unique features of the B cell developmental program and the transcriptional requirements of B cell differentiation.[12][23][25]

Early B cell development requires the expression of specific transcription factors including PAX5 and EBF1, which are essential for establishing and maintaining B cell identity.[12][23][25] These transcription factors are themselves encoded by exceptionally long genes that span more than 100 kilobases, placing them in the category of genes particularly dependent on TOP2B for efficient transcription.[12][23][25] A compelling hypothesis emerges from this observation: that B cell-specific defects in TOP2B deficiency arise from the inability to efficiently transcribe the long genes encoding PAX5 and EBF1 due to unresolved topological stress, resulting in insufficient expression of these critical B cell-specific transcription factors.[12][23][25] The downstream consequence of inadequate PAX5 and EBF1 expression in early B cell progenitors would be failure to establish B cell fate and a redirection toward alternative developmental pathways such as T cell or innate lymphoid cell differentiation, a default developmental route that B cell progenitors normally avoid through PAX5 and EBF1-mediated B cell fate commitment.[12][23][25]

Supporting this hypothesis is the observation that mice engineered to express reduced levels of both Pax5 and Ebf1 show B cell deficiencies with a developmental pattern and severity similar to those observed in TOP2B-deficient animals, suggesting that reduced expression of these genes can explain the B cell developmental block in TOP2B deficiency.[12][23][25] Additionally, TOP2B and the chromatin remodeler BRG1 interact directly and cooperate in transcription of the Pax5 and Ebf1 genes, indicating that TOP2B and chromatin remodeling machinery work in concert to enable efficient transcription of these critical B cell specification genes.[12][23][25]

B Cell Development and TOP2B at Chromatin Boundaries

Further insight into TOP2B function in B cell development comes from studies examining the role of TOP2B at TAD boundaries and in genome organization during B cell specification.[12][23][25] TOP2B colocalizes with CTCF and cohesin at TAD boundaries throughout the genome, and this colocalization is particularly important for the stability and integrity of chromatin architecture in developing B cells.[12][23][25] During the transition from hematopoietic multipotent progenitors to committed B cell progenitors, major rewiring of genome organization and chromatin contacts occurs, facilitating the activation of B cell-specific genes and the repression of genes encoding alternative cell fates.[12][23][25]

TOP2B may facilitate these reorganizations by resolving topological stress at TAD boundaries and by promoting the stability of newly formed chromatin loops and contacts that establish B cell-specific gene expression patterns.[12][23][25] The catalytic activity of TOP2B at TAD boundaries would remove the accumulation of supercoiling generated during chromatin loop extrusion mediated by cohesin, thereby stabilizing the three-dimensional genome organization required for proper execution of the B cell developmental program.[12][23][25]

Protein Interactions and Regulatory Mechanisms

Chromatin Architectural Protein Interactions

TOP2B functions within a complex network of protein-protein interactions that regulate its activity and localization to specific genomic sites.[10][12][31][37][47] One of the most significant interactions involves the architectural proteins CTCF and cohesin, which together organize the genome into topologically associating domains and establish long-range chromatin contacts between enhancers and promoters.[10][12][31][37][40][43] The interaction between TOP2B and cohesin subunits such as RAD21, STAG1, and STAG2, as well as cohesin loading factors including NIPBL and PDS5A, suggests that TOP2B recruitment to TAD boundaries and loop anchors is facilitated through direct protein-protein interactions with cohesin complexes.[10][31][37]

This interaction between TOP2B and cohesin may be bidirectional: TOP2B bound to TAD boundaries may recruit and stabilize cohesin, or alternatively, cohesin complexes may recruit TOP2B to sites where the accumulation of supercoiling necessitates topoisomerase activity.[10][12][37][40][43] The fact that approximately 50% of CTCF and cohesin binding sites at TAD boundaries are co-occupied by TOP2B, particularly at chromatin loop anchors that are conserved across multiple cell types and species, suggests that this relationship is not incidental but rather represents an important functional partnership in genome organization.[10][12][37][40][43]

Interaction with PARP and DNA Repair Factors

TOP2B associates functionally and physically with poly(ADP-ribose) polymerase (PARP) enzymes, particularly PARP1 and PARP2, and these interactions appear to be important for regulating TOP2B activity in response to its own catalytic products.[49] When TOP2B introduces double-strand breaks, the resulting breaks activate PARP enzymes, which then catalyze the synthesis of long branched polymers of poly(ADP-ribose) (PAR) attached to proteins at the break sites.[49] These PAR polymers, in turn, inhibit TOP2B activity, providing a feedback mechanism that limits the extent of TOP2B-mediated DNA cleavage and prevents excessive accumulation of double-strand breaks.[49]

The inhibition of TOP2B by activated PARP enzymes appears to be reversible and dynamic, as PAR polymers are continuously synthesized and degraded through the action of PARG (poly(ADP-ribose) glycohydrolase).[49] Cycles of PAR formation and degradation thus allow controlled bursts of TOP2B activity, coordinating DNA relaxation with histone removal and chromatin remodeling, processes that are important during spermatid differentiation and likely during other developmental processes involving major chromatin reorganization.[49] This PARP-regulated mechanism of TOP2B control may be particularly important during periods of high transcriptional activity or chromatin remodeling when extensive TOP2B-mediated DNA breaks occur.

Interaction with SUMO Ligase and TOP2cc Resolution

A crucial interaction in TOP2B biology is with the SUMO E3/E4 ligase ZATT (also known as ZNF451), which catalyzes SUMOylation of TOP2B and plays a critical role in resolving trapped TOP2B-DNA cleavage complexes.[39][42][50] When TOP2B is trapped on DNA by TOP2 poisons (anticancer drugs that prevent TOP2 religation) or by other mechanisms that stabilize TOP2ccs, the stalled cleavage complexes must be resolved to restore genomic integrity and allow cellular survival or appropriate cell death pathways.[39][42][50] ZATT binding to TOP2cc induces conformational changes that facilitate access of the phosphodiesterase TDP2 (tyrosyl-DNA phosphodiesterase 2) to the phosphotyrosyl bonds linking TOP2B to DNA.[39][42][50]

Furthermore, ZATT catalyzes poly-SUMOylation of TOP2B and TOP2ccs, with the enzyme showing marked preference for SUMOylation of stalled cleavage complexes over free TOP2B.[39][42][50] This SUMOylation enhances the recruitment of TDP2 to TOP2ccs through interactions between the SUMO2 chains and TDP2's SUMO-binding domains, creating a multivalent interface that promotes efficient engagement of TDP2 with the trapped cleavage complex.[39][42][50] TDP2 then catalyzes hydrolysis of the phosphotyrosyl bond, removing the TOP2B polypeptide and allowing ligation of the freed DNA ends through standard DNA repair machinery.[39][42][50] This ZATT-dependent pathway for TOP2cc resolution represents a critical protection mechanism against the genotoxic potential of TOP2-mediated DNA damage.

Notably, the ZATT-mediated downregulation of TOP2B activity during the estrogen transcriptional response represents a regulatory mechanism wherein ZATT is recruited to estrogen-responsive genes by estrogen receptor alpha and TOP2A, where it catalyzes SUMOylation of TOP2B to suppress its catalytic activity.[22][44][50] This allows accumulation of negative supercoiling at these sites, which in turn favors the formation and stabilization of long-range chromatin contacts required for full transcriptional activation of estrogen-responsive genes.[22][44] This intriguing mechanism reveals TOP2B as not merely a constitutively active enzyme but rather as a protein subject to sophisticated regulation by SUMO modifications that tune its activity in response to transcriptional demands.

Role in Three-Dimensional Genome Organization

Topologically Associating Domain Maintenance and Formation

Recent studies have established TOP2B as a critical regulator of three-dimensional genome organization, operating at the level of topologically associating domains and the long-range chromatin contacts that mediate enhancer-promoter interactions.[12][22][35][36][40][43][44] TADs are megabase-scale chromatin domains within which DNA sequences interact more frequently with each other than with sequences outside the domain, and they are formed through a process of cohesin-mediated loop extrusion that is guided and constrained by CTCF binding sites.[12][22][35][36][40][43][44] The boundaries of TADs are marked by clusters of CTCF and cohesin binding sites, where TOP2B is significantly enriched.[12][22][35][36][40][43]

The enrichment of TOP2B at TAD boundaries is not merely correlative but functionally important for maintaining proper TAD structure and compartmentalization.[12][22][35][36][40][43] As cohesin complexes extrude chromatin by translocating along the DNA fiber, they encounter topological constraints generated by the progressive accumulation of supercoiling ahead of the advancing cohesin ring.[12][22][35][36][40][43][44] This topological stress can impede the movement of cohesin and limit the processivity of loop extrusion.[12][22][35][36][40][43][44] TOP2B positioned at TAD boundaries resolves this accumulating supercoiling through its catalytic activity, thereby facilitating continued cohesin-mediated loop extrusion and allowing the formation and maintenance of TAD structure.[12][22][35][36][40][43][44]

A particularly clear demonstration of this TOP2B function comes from studies examining the estrogen transcriptional response, wherein TOP2B activity is dynamically regulated during the acute activation of estrogen-responsive genes.[19][22][44] Upon estrogen treatment, TOP2B activity is specifically downregulated at estrogen-responsive enhancers and promoters through ZATT-mediated SUMOylation, leading to accumulation of negative supercoiling at these sites.[22][44] This supercoiling-enriched environment then favors the formation and stabilization of long-range chromatin contacts between enhancers and target gene promoters, promoting the rapid and robust transcriptional activation characteristic of hormone-induced gene expression.[22][44] In the absence of functional TOP2B, this dynamic reorganization of chromatin contacts is impaired, and estrogen-responsive gene activation is substantially reduced.[22][44]

Genomic Fragility and Disease Implications

The association between TOP2B binding sites and genomic instability has recently emerged as an important consideration for understanding both cancer development and the mechanism of action of anticancer chemotherapy drugs.[40][43][44] Recent comprehensive studies examining TOP2B binding across thousands of cancer genomes reveal that TOP2B-occupied sites, particularly those at TAD boundaries and cooccupied with CTCF and cohesin (termed TOP2B-CTCF-RAD21 sites), are enriched in both somatic mutations and structural variants in cancer genomes.[43] This enrichment is particularly pronounced in actively transcribed genes and correlates with the transcriptional activity and frequency of chromatin interactions at these sites.[43]

This finding suggests that the catalytic activity of TOP2B, while essential for normal transcription and genome organization, inherently generates opportunities for genomic instability if the transient double-strand breaks introduced by TOP2B are not precisely controlled or repaired.[40][43][44] Under normal circumstances, the double-strand breaks formed by TOP2B are tightly regulated in timing and location, and they are rapidly repaired through NHEJ, preventing the conversion of transient breaks into permanent mutations or structural variants.[1][3][28] However, if TOP2B activity is dysregulated, if the recruitment of repair machinery is impaired, or if TOP2 poisons are present (such as during chemotherapy), these breaks can be converted into permanent genetic lesions.[14][26][28]

Clinical and Pharmacological Significance

TOP2 as an Anticancer Drug Target

TOP2B has emerged as a particularly important target for anticancer therapy through the development of TOP2 poison compounds, which include well-established clinical drugs such as etoposide, doxorubicin, and mitoxantrone.[1][14][17] These drugs function by stabilizing TOP2-DNA cleavage complexes, preventing the religation step of the TOP2 catalytic cycle and thereby converting transient TOP2-mediated breaks into stabilized, protein-linked double-strand breaks that trigger apoptosis in cancer cells.[14][17][28] Etoposide and related epipodophyllotoxin compounds have been standard chemotherapy agents for several decades and are used extensively in the treatment of various cancers including lung cancer, testicular cancer, lymphomas, and leukemias.[14][28]

The selectivity of TOP2 poisons for cancer cells reflects the fact that cancer cells typically have much higher rates of transcription than normal cells, and therefore accumulate TOP2-mediated breaks at higher frequencies, making them particularly vulnerable to drugs that prevent break repair.[14][22][28][31] Additionally, cancer cells frequently overexpress TOP2A due to their ongoing DNA replication during active cell division, and many TOP2 poisons preferentially trap TOP2A over TOP2B, providing selectivity for cancer cells over normal cells with lower TOP2A expression.[14][28][31]

However, a notable recent discovery is that a novel drug compound called CX-5461, originally developed as an RNA polymerase I inhibitor, preferentially inhibits TOP2B catalytic activity compared to TOP2A, with a 2- to 4-fold selectivity for TOP2B over TOP2A.[17] This selective TOP2B inhibition appears to be particularly effective against neuroblastoma cells, which highly express TOP2B but have lower expression of TOP2A.[17] The discovery of compounds with differential selectivity for TOP2A versus TOP2B opens new possibilities for more targeted cancer therapy that could exploit the tissue-specific and functional differences between these two topoisomerase isoforms.

Secondary Malignancies and Treatment-Related Leukemia

A significant clinical concern associated with treatment using TOP2 poison drugs is the increased risk of secondary malignancies, particularly treatment-related acute leukemias (tAML), which can develop years after chemotherapy treatment.[14][28] These secondary leukemias frequently harbor specific chromosomal translocations involving the MLL (mixed lineage leukemia) gene on chromosome 11, as well as translocations at other recurrent breakpoints.[14][28] Molecular analysis of these translocations reveals that they frequently occur at sites where TOP2A and TOP2B are enriched and where TOP2-mediated DNA breaks accumulate in response to chemotherapy drugs.[14][21][28][31][37]

The mechanistic basis for TOP2 poison-induced chromosomal translocations involves the formation of double-strand breaks at two or more genomic loci that are subsequently joined incorrectly by nonhomologous end joining, resulting in genomic rearrangements.[14][21][28][31][37] The spatial proximity of sites where TOP2-mediated breaks occur on different chromosomes, combined with the incomplete or delayed repair of these breaks, increases the probability that breaks at distant sites will be inappropriately joined together, creating translocations.[14][21][28][31][37] This mechanism explains why translocations frequently occur at genomic sites with high TOP2 binding and high transcriptional activity, where TOP2 catalytic activity and break formation are most intense.[14][21][28][31][37]

Understanding the molecular mechanisms linking TOP2B-mediated DNA breaks to chromosomal translocations and secondary malignancies has important implications for optimizing chemotherapy regimens and for developing strategies to prevent or minimize secondary malignancy risk in cancer survivors.[14][28]

Cellular ATP Regulation and Nucleolar Dynamics

The ATP-dependent regulation of TOP2B subcellular localization represents a sophisticated mechanism for coupling enzyme activity to cellular energy status.[3][9][34] When cells experience periods of energy depletion or stress, the rapid translocation of TOP2B from the metabolically expensive nucleoplasm to the quiescent nucleolus provides a mechanism for downregulating TOP2B catalytic activity while conserving cellular energy.[3][9][34] This ATP-dependent regulation has direct consequences for TOP2B function in transcription, as genes actively requiring TOP2B for transcription-associated topological relaxation experience reduced TOP2B activity during energy stress, providing a metabolic checkpoint for the regulation of transcription.[3][9][34]

The molecular details of this regulation involve the C-terminal RNA-binding domain of TOP2B, which mediates interactions with nucleolar RNA and appears to sense or be responsive to the ATP status of the cell.[3][9][34] The energy status of the cell may influence the binding of ATP and other nucleotides to TOP2B's N-terminal ATPase domain, potentially leading to conformational changes that alter the affinity of TOP2B for RNA or for specific genomic sites.[3][9][34] Additionally, cellular signaling cascades responding to energy stress, such as AMP-activated protein kinase (AMPK) signaling, may directly phosphorylate TOP2B or regulatory proteins that control its localization, providing another layer of regulation linking energy status to TOP2B activity.[3][9][34]

This ATP-dependent regulation of TOP2B activity has potential implications for understanding how cells coordinate transcriptional programs with metabolic status, and for understanding how metabolic diseases and aging might perturb transcriptional regulation through dysregulation of TOP2B activity and localization.[21]

Recent Discoveries and Emerging Models

Structural Insights and Mechanism Clarification

Recent high-resolution cryo-electron microscopy structures of TOP2B in complex with DNA have provided unprecedented mechanistic insights into how the enzyme binds to DNA, positions catalytic residues for cleavage, and facilitates strand passage.[28][32][48] These structural studies reveal that TOP2B undergoes massive conformational changes during its catalytic cycle, including dramatic bending and unwinding of the DNA substrate, repositioning of the catalytic tyrosine residue into the active site, and coordinated movements of the N-gate and C-gate domains that regulate passage of the DNA through the transient break.[28][32][48]

Notably, structural studies of TOP2B bound to DNA in the presence of transcriptionally active RNA polymerase II reveal intimate physical contacts between TOP2B and the polymerase, indicating that these enzymes do not work independently but rather function as part of a coordinated enzymatic complex that couples transcriptional elongation with topological relaxation.[28][35][48] This physical interaction between TOP2B and RNA Pol II likely provides a mechanism for local recruitment of TOP2B to sites where polymerase-mediated topological stress is actively being generated, ensuring that topoisomerase activity is precisely positioned and timed to address the topological problems created during transcription.

TOP2B in Aging and Longevity

Emerging evidence suggests that TOP2B function may play a role in aging processes and cellular aging.[21] Studies in model organisms demonstrate that reduction of TOP2B expression or activity can recapitulate some aspects of a youthful epigenetic and transcriptional state in aged tissues, with TOP2B knockdown animals showing reduced accumulation of age-associated epigenetic modifications and altered transcriptional patterns characteristic of young animals.[21] These findings suggest that dysregulation or decline of TOP2B activity during aging may contribute to the accumulation of alterations in chromatin state and transcriptional programs that characterize cellular aging.[21]

This emerging connection between TOP2B and aging is mechanistically interesting because TOP2B's role in maintaining proper transcriptional states and chromatin organization throughout life may be directly relevant to the maintenance of genomic and epigenomic stability that is critical for preventing age-associated diseases and cellular dysfunction.[21]

Conclusion

DNA topoisomerase II-beta (TOP2B) is a highly specialized nuclear enzyme that solves the fundamental problem of DNA topological constraint through a sophisticated catalytic mechanism involving transient double-strand break formation, strand passage, and rapid religation.[1][2][3] The enzyme occupies unique and essential roles in cell biology that extend far beyond simple topological relaxation, functioning as a critical regulator of signal-dependent transcriptional activation, a maintainer of three-dimensional genome organization, a mediator of developmental transcriptional programs in specific cell lineages, and a critical player in neuronal activity-dependent gene expression underlying learning and memory.[1][2][7][10][11][22][25][55][58] Unlike its paralog TOP2A, which is primarily engaged in DNA replication-associated processes in proliferating cells, TOP2B exhibits constitutive expression in both dividing and non-dividing cells and has evolved specialized functions in transcription and genome organization that are particularly critical in postmitotic cells such as neurons.[1][7][9][33]

Recent discoveries have revealed TOP2B as far more than a constitutively active enzyme; rather, it is subject to sophisticated multilayered regulation by phosphorylation, SUMOylation, interactions with transcription factors and architectural proteins, and ATP-dependent subcellular localization.[22][39][42][48][58] The tissue-specific and gene-specific requirements for TOP2B function are reflected in the striking clinical phenotypes observed in TOP2B deficiency disorders, wherein B cell development is uniquely impaired while other cell lineages are relatively spared, highlighting the specialized dependencies of different cell types on TOP2B catalytic activity.[12][20][23][25][46] As both a promising target for anticancer therapeutics and a key regulator of critical transcriptional programs in development and neuronal function, TOP2B represents an important subject for continued research aimed at understanding both its normal biological roles and its dysregulation in disease.

Citations

1. https://en.wikipedia.org/wiki/TOP2B
2. https://maayanlab.cloud/Harmonizome/gene/TOP2B
3. https://pmc.ncbi.nlm.nih.gov/articles/PMC4132749/
4. https://www.uniprot.org/uniprotkb/Q02880/entry
5. https://www.alliancegenome.org/gene/HGNC:11990
6. https://www.nature.com/articles/s41467-024-49816-7
7. https://pmc.ncbi.nlm.nih.gov/articles/PMC3340998/
8. https://www.nature.com/articles/s41598-021-00958-4
9. https://portlandpress.com/biochemsoctrans/article/49/6/2483/230165/TOP2B-s-contributions-to-transcription
10. https://pmc.ncbi.nlm.nih.gov/articles/PMC6895833/
11. https://pmc.ncbi.nlm.nih.gov/articles/PMC9423374/
12. https://pmc.ncbi.nlm.nih.gov/articles/PMC2730144/
13. https://pmc.ncbi.nlm.nih.gov/articles/PMC2748742/
14. https://www.ncbi.nlm.nih.gov/gene/7155
15. https://www.nature.com/articles/s41467-025-62505-3
16. https://www.nature.com/articles/s41467-021-26640-x
17. https://www.science.org/doi/10.1126/sciadv.adu6524
18. https://pmc.ncbi.nlm.nih.gov/articles/PMC6692411/
19. https://elifesciences.org/reviewed-preprints/103979
20. https://pmc.ncbi.nlm.nih.gov/articles/PMC10849543/
21. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.982870/full
22. https://pmc.ncbi.nlm.nih.gov/articles/PMC2932731/
23. https://pmc.ncbi.nlm.nih.gov/articles/PMC3100707/
24. https://www.science.org/doi/10.1126/sciadv.add4920
25. https://elifesciences.org/reviewed-preprints/91304v1.pdf
26. https://pubmed.ncbi.nlm.nih.gov/21610027/
27. https://pmc.ncbi.nlm.nih.gov/articles/PMC9629710/
28. https://pmc.ncbi.nlm.nih.gov/articles/PMC9592559/
29. https://onlinelibrary.wiley.com/doi/10.1111/joa.12416
30. https://academic.oup.com/nar/article/42/14/9005/1287871
31. https://pmc.ncbi.nlm.nih.gov/articles/PMC11971153/
32. https://pmc.ncbi.nlm.nih.gov/articles/PMC3615473/
33. https://pmc.ncbi.nlm.nih.gov/articles/PMC5623066/
34. https://pmc.ncbi.nlm.nih.gov/articles/PMC11040008/
35. https://genesdev.cshlp.org/content/6/7/1332
36. https://www.science.org/doi/10.1126/science.aam6468
37. https://www.nature.com/articles/s41467-025-65005-6
38. https://pmc.ncbi.nlm.nih.gov/articles/PMC12652261/
39. https://pubmed.ncbi.nlm.nih.gov/7660411/
40. https://pmc.ncbi.nlm.nih.gov/articles/PMC7612232/
41. https://pmc.ncbi.nlm.nih.gov/articles/PMC10721843/
42. https://pmc.ncbi.nlm.nih.gov/articles/PMC3080419/
43. https://pmc.ncbi.nlm.nih.gov/articles/PMC3529160/
44. https://cdnsciencepub.com/doi/10.1139/o05-038
45. https://pmc.ncbi.nlm.nih.gov/articles/PMC9638942/
46. https://pmc.ncbi.nlm.nih.gov/articles/PMC4090310/
47. https://pmc.ncbi.nlm.nih.gov/articles/PMC8248687/
48. https://pubmed.ncbi.nlm.nih.gov/15520013/
49. https://pmc.ncbi.nlm.nih.gov/articles/PMC1891346/
50. https://pmc.ncbi.nlm.nih.gov/articles/PMC9990814/
51. https://pmc.ncbi.nlm.nih.gov/articles/PMC10657183/
52. https://pmc.ncbi.nlm.nih.gov/articles/PMC9683059/